Hemodialysis and hemofiltration membranes based upon a two-dimensional membrane material and methods employing same

Information

  • Patent Grant
  • 10005038
  • Patent Number
    10,005,038
  • Date Filed
    Wednesday, September 2, 2015
    8 years ago
  • Date Issued
    Tuesday, June 26, 2018
    5 years ago
Abstract
Perforated graphene and other perforated two-dimensional materials can be used in hemodialysis membranes and blood filtration membranes for selective removal of components from blood in vivo and ex vivo. The membranes are useful in hemodialysis and hemofiltration techniques to provide improved patient care. Hemodialysis systems can include a hemodialysis membrane formed from perforated graphene or another perforated two-dimensional material disposed upon a porous support structure. Hemofiltration systems can include one or more and preferably two or more blood filtration membrane formed from perforated graphene or another perforated two-dimensional material disposed upon a porous support structure. Methods for performing hemodialysis can involve exposing blood from a patient to a hemodialysis membrane formed from a perforated two-dimensional material. Ex vivo dialysis techniques can be performed similarly. Methods for filtration of blood can involve passing blood through one or more filter membranes or through a plurality of sequential filter membranes.
Description
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not applicable.


FIELD

The present disclosure generally relates to the use of nanomaterials in medical applications, and, more specifically, to hemodialysis and hemofiltration membranes based upon graphene-based materials and other two-dimensional materials.


BACKGROUND

Hemodialysis is one of the most common treatments provided in medical facilities today, and the market for such treatments continues to grow. The 2013 global dialysis market is valued at $61.60 billion and is expected to grow at a compound annual growth rate (CAGR) of 6.2% over the next five years with the increasing number of end stage renal disease (ESRD) patients and the rising prevalence of diabetes and hypertension worldwide. In addition, growth in the number of dialysis facilities in developed as well as developing markets, increasing private investments, and venture funding to support new product development is contributing to the growth of the global market. Reduced insurance disbursements to dialysis centers, high treatment costs, and low awareness of kidney related diseases and their treatment modalities are factors that continue to restrain market growth.


Hemofiltration is typically employed with patients exhibiting acute kidney injury. In hemofiltration, water and relatively low molecular weight components (up to 20-30 kDa) are removed by convection through a hemofiltration membrane. Water and electrolytes are replaced in the patient. Hemofiltration may be combined with hemodialysis.



FIG. 1 shows an illustrative schematic of a conventional hemodialysis system and technique. In the illustrated system blood is passed from the patient via an appropriate conduit (11) by action of pump (3) into a dialyzer unit (5) which contains an appropriate filter (2), typically a hallow fiber filter, to selectively remove toxic species from the blood. Fresh dialysate is passed, employing pump (7), into the dialyzer via appropriate conduit (14) and used dialysate exits the dialyzer unit via appropriate conduit (12). A dialysate source (22) and waste receptacle (21) are optionally provided. Cleaned blood is returned to the patient via appropriate conduit (13) through an air detector and trap (9). In flow pressure into the dialyzer, venous pressure and arterial pressure are monitored (4, 6 and 8, respectively). A source of saline (16) and heparin (17) are provided via saline conduit (15) as needed via valves or related fluid metering devices (18 and 19) to prevent clotting. FIG. 2 shows an expanded schematic of a conventional hemodialysis membrane (30), having pores (32) of selected dimension to allow passage of ions (33), small molecules (34) and prevent passage of larger macromolecules (35). The thickness (t) of the convention membrane is in the range of 50 micron. Current state solutions, or dialyzers, are hollow fiber membrane (30) devices in a hard plastic shell. Blood flows through the lumen of the fiber and dialysate flows through the dialyzer on the exterior of the fibers. Fibers are traditionally made of porous materials such as cellulose triacetate, polysulfone, polyethersulfone, polymethylmethacrylate, polyester polymer alloy, ethylene vinyl alcohol copolymer or polyacrylonitrile. The fibers have a microporous structure that allows small molecules to diffuse from the blood into the dialysate. The diffusion rate can be expressed in terms of the dialyzer clearance of the molecules. Clearances of various molecules can occur at different rates under various blood and dialysate flow rate conditions. The large variety of dialyzer configurations permits physicians to appropriately specify a hemodialysis treatment to meet the needs of a patient. There is an entire system built around this filter technology to provide the current standard of care to patients. However, the performance is limited by the permeability, selectivity and roughness of the dialyzer membrane.


In view of the foregoing, improved hemodialysis membranes and hemofiltration membranes and methods would be of considerable benefit in the art. In particular, hemodialysis membranes and hemofiltration membranes having increased permeability and selectivity would be especially advantageous. The present disclosure satisfies the foregoing needs and provides related advantages as well.


SUMMARY

The present disclosure describes membranes comprising a perforated two-dimensional material disposed upon a porous support structure for use in blood dialysis and blood filtration applications. Such two-dimensional materials are selectively perforated to provide for selective removal of one or more components from the blood. Two-dimensional materials include for example graphene-based materials.


In one aspect the disclosure describes hemodialysis membranes and systems in which perforated graphene-based material and other perforated two-dimensional materials are used as a replacement for polymer membranes in conventional hemodialysis systems. The perforated two-dimensional material, such as graphene-based material and graphene, can have a pore size of similar magnitude to those used in conventional membranes, while providing much greater permeability due the thinness of the graphene. In addition, the pores or perforations in the two-dimensional material, such as graphene-based material, can be selectively sized, functionalized, or otherwise manipulated to tailor the selectivity of the hemodialysis separation process.


The present disclosure also describes hemodialysis methods in which blood is exposed to a hemodialysis membrane formed from perforated two-dimensional material, such as graphene-based material, and at least one component is removed from the blood upon contacting the perforated graphene. In an embodiment, the at least on component removed is urea, measurement of the extent of removal of which can be used to assess the effectiveness of a given hemodialysis method to remove low molecular weight toxic species, e.g., low molecular weight toxic species which contribute to disease. In an embodiment, at least one undesirable component is removed, such as a low molecular weight toxic species or a lower molecular weight (e.g., less than about 35 kDa) protein which contributes to uremia or other disorder, without removal of albumin at levels detrimental to a given patient. In an embodiment, at least urea is removed without removal of detrimental levels of albumin.


The foregoing has outlined rather broadly the features of the present disclosure in order that the detailed description that follows can be better understood. Additional features and advantages of the disclosure will be described hereinafter. These and other advantages and features will become more apparent from the following description.





BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding of the present disclosure, and the advantages thereof, reference is now made to the following descriptions to be taken in conjunction with the accompanying drawings describing specific embodiments of the disclosure, wherein:



FIG. 1 shows an illustrative schematic of a conventional hemodialysis system and technique;



FIG. 2 shows an expanded schematic of a conventional hemodialysis membrane. In this schematic a dialysis membrane is illustrated to have pores of selected dimension (diameter of for example about 2.4 nm) which allows passage of ions, such as Na+; small molecules, such as urea, but does not allow passage of globular macromolecules, such as serum albumin. Conventional hemodialysis membranes have thickness (t) in the range of 50 micron



FIG. 3 shows an illustrative scanning electron microscope (SEM) image of perforated single-layer graphene-based material on a track-etched polycarbonate support structure;



FIGS. 4A-E show images of single layer graphene (nominal thickness of about 0.3 nm) and pores therein. FIG. 4A is a scanning transmission electron microscope (STEM) image of single-layer graphene with pores of about 1 nm. FIG. 4B is a micrograph of CDV graphene-based material exhibiting pores ranging from about 0.5 to 1 nm in dimension. FIG. 4C is a micrograph of CDV graphene-based material exhibiting pores ranging from 2.5 to 7 nm in dimension. FIG. 4D is a micrograph of CDV graphene-based material exhibiting a mean pore size dimension of 6.3 nm, and which is about 4% open with about 1×1011 pores/cm2. Perforations are generated in the CDV graphene of FIGS. 4A-D using ion beam irradiation. FIG. 4E is a micrograph of CDV graphene-based material in which pores were introduced using focused ion beam (FIB) drilling and where the average pores size is 20 nm.



FIG. 5 shows an illustrative hemodialysis system containing a graphene-based membrane (55) and a two-chamber cross-flow vessel (51). This figure also illustrates an optional multiple pass hemodialysis configuration, implemented via optional conduit (65) in which used dialysate is mixed with fresh dialysate to decrease water use.



FIG. 6 shows an illustrative blood filtration configuration comprising two or more (6 are shown) graphene-based membranes (71A-71F) each of which have different pore dimensions, for example, where average pore dimension increases from 71A to 71F. Passage of blood through the filter configuration generates two or more flow streams (6 are shown, 72A-72F) containing size separated components dependent upon the pore dimensions of the filters. For example, where average pore dimension increases from 71A to 71F, the flow streams from 72A-72F will contain components of decreasing size.





DETAILED DESCRIPTION

The present disclosure is directed to membranes comprising a perforated two-dimensional material disposed upon a porous support structure for use in blood dialysis and blood filtration applications. Such two-dimensional materials are selectively perforated to provide for selective removal of one or more components from the blood. In specific embodiments, such two-dimensional materials are selectively perforated to provide for selective removal of one or more selected undesirable components from blood while retaining one or more selected desirable components in the blood.


The present disclosure is directed, in part, to hemodialysis membranes and hemodialysis systems containing selectively perforated graphene or another selectively perforated two-dimensional material. The present disclosure is also directed, in part, to methods for performing a hemodialysis treatment using a hemodialysis system containing such perforated graphene or another such perforated two-dimensional material. Methods herein include hemodialysis cross flow configurations. Methods herein include single-pass methods in which used dialysate is not recirculated and multi-pass systems in which used dialysate is mixed with fresh dialysate and reused.


The present disclosure is directed, in part, to blood filtration membranes and blood filtration systems containing selectively perforated graphene or another selectively perforated two-dimensional material. The present disclosure is also directed, in part, to methods for performing a hemodialysis treatment using a hemodialysis system containing such perforated graphene or another such perforated two-dimensional material


Graphene has garnered widespread interest for use in a number of applications due to its favorable mechanical and electronic properties. Graphene represents an atomically thin layer of carbon (or few carbon layers) in which the carbon atoms reside as closely spaced atoms at regular lattice positions. The regular lattice positions can have a plurality of defects present therein, which can occur natively or be intentionally introduced to the graphene basal plane. Such defects will also be equivalently referred to herein as “apertures,” “perforations,” or “holes.” The term “perforated graphene” will be used herein to denote a graphene sheet with defects in its basal plane, regardless of whether the defects are natively present or intentionally produced. Aside from such apertures, graphene and other two-dimensional materials (e.g., graphene oxide and the like) can represent an impermeable layer to many substances. Therefore, if they are sized properly, the apertures in the impermeable layer can be useful in retaining entities that are larger than the effective pore size. In this regard, a number of techniques have been developed for introducing a plurality of perforations in graphene and other two-dimensional materials, where the perforations have a desired size, number and chemistry about the perimeter of the perforations. Chemical modification of the apertures can allow entities having particular chemical characteristics to be preferentially retained or rejected as well.


Two-dimensional materials are, most generally, those which are atomically thin, with thickness from single-layer sub-nanometer thickness to a few nanometers, and which generally have a high surface area. Two-dimensional materials include metal chalogenides (e.g., transition metal dichalogenides), transition metal oxides, hexagonal boron nitride, graphene, silicene and germanene (see: Xu et al. (2013) “Graphene-like Two-Dimensional Materials) Chemical Reviews 113:3766-3798). Graphene represents a form of carbon in which the carbon atoms reside within a single atomically thin sheet or a few layered sheets (e.g., about 20 or less) of fused six-membered rings forming an extended sp2-hybridized carbon planar lattice. In its various forms, graphene has garnered widespread interest for use in a number of applications, primarily due to its favorable combination of high electrical and thermal conductivity values, good in-plane mechanical strength, and unique optical and electronic properties. Other two-dimensional materials having a thickness of a few nanometers or less and an extended planar lattice are also of interest for various applications. In an embodiment, a two dimensional material has a thickness of 0.3 to 1.2 nm. In other embodiments, a two dimensional material has a thickness of 0.3 to 3 nm.


In various embodiments, the two-dimensional material comprises a sheet of a graphene-based material. In an embodiment, the sheet of graphene-based material is a sheet of single- or multi-layer graphene or a sheet comprising a plurality of interconnected single- or multi-layer graphene domains. In embodiments, the multilayer graphene domains have 2 to 5 layers or 2 to 10 layers. In an embodiment, the layer comprising the sheet of graphene-based material further comprises non-graphenic carbon-based material located on the surface of the sheet of graphene-based material. In an embodiment, the amount of non-graphenic carbon-based material is less than the amount of graphene. In embodiments, the amount of graphene in the graphene-based material is from 60% to 95% or from 75% to 100%.


The technique used for forming the graphene or graphene-based material in the embodiments described herein is not believed to be particularly limited. For example, in some embodiments CVD graphene or graphene-based material can be used. In various embodiments, the CVD graphene or graphene-based material can be liberated from its growth substrate (e.g., Cu) and transferred to a polymer backing. In some embodiments, the growth substrate may be corrugated before or after the graphene deposition process to produce a graphene or graphene-based material with high surface area. In some embodiments, a growth substrate may be formed as a cylinder to form a sleeve of graphene or graphene-based material, thereby reducing the number of seams that must be sealed to form the enclosure.


The present inventors recognized that many of the techniques used to introduce perforations into graphene-based material and other two-dimensional materials produce perforations having pore sizes similar to those present in conventional hemodialysis membranes. Thus, they can be used for separating impurities having comparable size to those separated using conventional hemodialysis membranes. However, since single-layer or even multi-layer graphene are much thinner than conventional hemodialysis membranes, a much greater transfer rate can be realized, as expressed with the following formula.











Impurity





Transport







Q
=




Kd
2


A





ɛ

t



(


Δ





P

-

RT





Δ





C


)








Q
=

Impurity





flow






(

ml


/


sec

)









K
=

Membrane






Permeability
/
pore






area








A
=

Membrane





Area






(

m





2

)









ɛ
=
porosity








Δ





P

=

transmembrane





pressure






(
Pa
)










Δ





C

=

solute





transmembrane





concentration








t
=

membrane





thickness






[
3
]








Hence, very thin graphene membranes allow for a much greater transport rate to be realized, which can be least 1000 times faster than in conventional hemodialysis membranes. In an embodiment, the graphene membranes can be used as a drop-in replacement for conventional hemo dialysis membranes.


In addition to the increased transport rate, the size selectivity can advantageously allow decreased collateral metabolite loss to occur during dialysis. Further, the smoothness of the graphene membrane can allow for a lower anticoagulant load to be used during a dialysis procedure, and a reduced incidence of clotting can be realized. Finally, as a result of the foregoing, hemodialysis systems with a decreased footprint size and lower power requirements can be realized. Decreased patient treatment times can ultimately result. Any of these factors can increase profitability of hemodialysis centers.


Likewise, the techniques for introducing perforations to the graphene or graphene-based material are also not believed to be particularly limited, other than being chosen to produce perforations within a desired size range. Perforations are sized as described herein to provide desired selective permeability of a species (atom, molecule, protein, virus, cell, etc.) for a given application. Selective permeability relates to the propensity of a porous material or a perforated two-dimensional material to allow passage (or transport) of one or more species more readily or faster than other species. Selective permeability allows separation of species which exhibit different passage or transport rates. In two-dimensional materials selective permeability correlates to the dimension or size (e.g., diameter) of apertures and the relative effective size of the species. Selective permeability of the perforations in two-dimensional materials, such as graphene-based materials, can also depend on functionalization of perforations (if any) and the specific species that are to be separated. Separation of two or more species in a mixture includes a change in the ratio(s) (weight or molar ratio) of the two or more species in the mixture after passage of the mixture through a perforated two-dimensional material.


Graphene-based materials include, but are not limited to, single layer graphene, multilayer graphene or interconnected single or multilayer graphene domains and combinations thereof. In an embodiment, graphene-based materials also include materials which have been formed by stacking single layer or multilayer graphene sheets. In embodiments, multilayer graphene includes 2 to 20 layers, 2 to 10 layers or 2 to S layers. In embodiments, graphene is the dominant material in a graphene-based material. For example, a graphene-based material comprises at least 30% graphene, or at least 40% graphene, or at least 50% graphene, or at least 60% graphene, or at least 70% graphene, or at least 80% graphene, or at least 90% graphene, or at least 95% graphene. In embodiments, a graphene-based material comprises a range of graphene selected from 30% to 95%, from 40% to 80%, from 50% to 70%, from 60% to 95% or from 75% to 100%.


As used herein, a “domain” refers to a region of a material where atoms are uniformly ordered into a crystal lattice. A domain is uniform within its boundaries, but different from a neighboring region. For example, a single crystalline material has a single domain of ordered atoms. In an embodiment, at least some of the graphene domains are nanocrystals, having domain size from 1 to 100 nm or 10 to 100 nm. In an embodiment, at least some of the graphene domains have a domain size greater than 100 nm to 1 micron, or from 200 nm to 800 nm, or from 300 nm to 500 nm. “Grain boundaries” formed by crystallographic defects at edges of each domain differentiate between neighboring crystal lattices. In some embodiments, a first crystal lattice may be rotated relative to a second crystal lattice, by rotation about an axis perpendicular to the plane of a sheet, such that the two lattices differ in “crystal lattice orientation”.


In an embodiment, the sheet of graphene-based material comprises a sheet of single layer or multilayer graphene or a combination thereof. In an embodiment, the sheet of graphene-based material is a sheet of single layer or multilayer graphene or a combination thereof. In another embodiment, the sheet of graphene-based material is a sheet comprising a plurality of interconnected single or multilayer graphene domains. In an embodiment, the interconnected domains are covalently bonded together to form the sheet. When the domains in a sheet differ in crystal lattice orientation, the sheet is polycrystalline.


In embodiments, the thickness of the sheet of graphene-based material is from 0.34 to 10 nm, from 0.34 to 5 nm, or from 0.34 to 3 nm. In an embodiment, a sheet of graphene-based material comprises intrinsic defects. Intrinsic defects are those resulting from preparation of the graphene-based material in contrast to perforations which are selectively introduced into a sheet of graphene-based material or a sheet of graphene. Such intrinsic defects include, but are not limited to, lattice anomalies, pores, tears, cracks or wrinkles. Lattice anomalies can include, but are not limited to, carbon rings with other than 6 members (e.g. 5, 7 or 9 membered rings), vacancies, interstitial defects (including incorporation of non-carbon atoms in the lattice), and grain boundaries.


In an embodiment, the layer comprising the sheet of graphene-based material further comprises non-graphenic carbon-based material located on the surface of the sheet of graphene-based material. In an embodiment, the non-graphenic carbon-based material does not possess long range order and may be classified as amorphous. In embodiments, the non-graphenic carbon-based material further comprises elements other than carbon and/or hydrocarbons. Non-carbon elements which may be incorporated in the non-graphenic carbon include, but are not limited to, hydrogen, oxygen, silicon, copper and iron. In embodiments, the non-graphenic carbon-based material comprises hydrocarbons. In embodiments, carbon is the dominant material in non-graphenic carbon-based material. For example, a non-graphenic carbon-based material comprises at least 30% carbon, or at least 40% carbon, or at least 50% carbon, or at least 60% carbon, or at least 70% carbon, or at least 80% carbon, or at least 90% carbon, or at least 95% carbon. In embodiments, a non-graphenic carbon-based material comprises a range of carbon selected from 30% to 95%, or from 40% to 80%, or from 50% to 70%.


Such nanomaterials in which pores are intentionally created will be referred to herein as “perforated graphene”, “perforated graphene-based materials” or “perforated two-dimensional materials.” The present disclosure is also directed, in part, to perforated graphene, perforated graphene-based materials and other perforated two-dimensional materials containing a plurality of holes of size (or size range) appropriate for a given enclosure application. The size distribution of holes may be narrow, e.g., limited to a 1-10% deviation in size or a 1-20% deviation in size. In an embodiment, the characteristic dimension of the holes is selected for the application. For circular holes, the characteristic dimension is the diameter of the hole. In embodiments relevant to non-circular pores, the characteristic dimension can be taken as the largest distance spanning the hole, the smallest distance spanning the hole, the average of the largest and smallest distance spanning the hole, or an equivalent diameter based on the in-plane area of the pore. As used herein, perforated graphene-based materials include materials in which non-carbon atoms have been incorporated at the edges of the pores.


In various embodiments, the two-dimensional material comprises graphene, molybdenum disulfide, or boron nitride. In more particular embodiments, the two-dimensional material can be graphene. Graphene according to the embodiments of the present disclosure can include single-layer graphene, multi-layer graphene, or any combination thereof. Other nanomaterials having an extended two-dimensional molecular structure can also constitute the two-dimensional material in the various embodiments of the present disclosure. For example, molybdenum sulfide is a representative chalcogenide having a two-dimensional molecular structure, and other various chalcogenides can constitute the two-dimensional material in the embodiments of the present disclosure. Choice of a suitable two-dimensional material for a particular application can be determined by a number of factors, including the chemical and physical environment into which the graphene or other two-dimensional material is to be terminally deployed. For application in the present invention, materials employed in making an enclosure are preferably biocompatible or can be made biocompatible.


The process of forming holes in graphene and other two-dimensional materials will be referred to herein as “perforation,” and such nanomaterials will be referred to herein as being “perforated.” In a graphene sheet an interstitial aperture is formed by each six-carbon atom ring structure in the sheet and this interstitial aperture is less than one nanometer across. In particular, this interstitial aperture is believed to be about 0.3 nanometers across its longest dimension (the center to center distance between carbon atoms being about 0.28 nm and the aperture being somewhat smaller than this distance). Perforation of sheets comprising two-dimensional network structures typically refers to formation of holes larger than the interstitial apertures in the network structure.


Due to the atomic-level thinness of graphene and other two-dimensional materials, it can be possible to achieve high liquid throughput fluxes during separation or filtration processes, even with holes that are in the ranges of 1-200 nm, 1-100 nm, 1-50 nm, or 1-20 nm.


Chemical techniques can be used to create holes in graphene and other two-dimensional materials. Exposure of graphene or another two-dimensional material to ozone or atmospheric pressure plasma (e.g., an oxygen/argon or nitrogen/argon plasma) can effect perforation. Other techniques, such as ion bombardment, can also be used to remove matter from the planar structure of two-dimensional materials in order to create holes. All such methods can be applied for preparation of perforated two-dimensional materials for use herein dependent upon the hole sizes or range of hole sizes desired for a given application. The terms holes, pores, apertures and perforations are used interchangeably herein.


In various embodiments of the present disclosure, the holes produced in the graphene-based material or other two-dimensional material can range from about 0.3 nm to about 50 nm in size. In a more specific embodiment, hole sizes can range from 1 nm to 50 nm. In a more specific embodiment, hole sizes can range from 1 nm to 10 nm. In a more specific embodiment, hole sizes can range from 5 nm to 10 nm. In a more specific embodiment, hole sizes can range from 1 nm to 5 nm. In a more specific embodiment, the holes can range from about 0.5 nm to about 2.5 nm in size. In an additional embodiment, the hole size is from 0.3 to 0.5 nm. In a further embodiment, the hole size is from 0.5 to 10 nm. In an additional embodiment, the hole size is from 5 nm to 20 nm. In a further embodiment, the hole size is from 0.7 nm to 1.2 nm. In an additional embodiment, the hole size is from 10 nm to 50 nm.



FIG. 3 shows an illustrative SEM image of perforated single-layer graphene on a track-etched polycarbonate support structure. Such configurations can be used as a hemodialysis membrane in various embodiments of the present disclosure. In general, any porous support structure that is suitably biocompatible with blood can be used as a support for the perforated graphene in the various embodiments of the membranes described herein. FIG. 4A shows a high magnification STEM image of the single-layer graphene and the pores therein. FIGS. 4B-4D are micrographs of single-layer graphene exhibiting different pore dimension ranges (or average pore dimension) and different pore densities. FIG. 4B illustrates CDV graphene-based material perforated with ion beam (Xe, 500V accelerating voltage, (60 nAs=3.75×1013 ions/cm2), neutralizer used), while suspended with background gas (air at 1×10-4 Torr). FIG. 4C illustrates CVD graphene-based material perforated with ion beam (Xe 500V, 60 nAs fluence (52 nA flux for 1.14 sec), no neutralizer used) while suspended with background gas (air at 1×10-4 Torr). FIG. 4D illustrates CDV graphene-based material perforated with ion beam (high-fluence (2000 nAs=1.25×1015 ions/cm2), low energy (20V accelerating voltage) Xe ions) while suspended.


Methods for perforating two-dimensional materials, including graphene-based materials and graphene have been described in the art and include among others, irradiation with ions, bombardment with particles, etching processes and focus ion beam drilling. Methods which allowing formation of pores or perforations of a selected size (dimension) are preferred. Pores may have any useful shape and may be substantially round or may be elongated, e.g., slit-shaped. The terms size and dimension of a pore refer to the widest dimension of the pore which depend upon the shape of the pore. The widest dimension of a round pore is the diameter of the round pore. In preferred embodiments, pore dimensions in dialysis membranes and filters range from about 1 nm to about 30 nm, or from about 1 nm to about 20 nm, or from about 1 nm to about 10 nm or from 1 nm to about 7 nm. In more specific embodiments, pores dimensions in the membranes and filters herein range up to 7 nm.


In an embodiment, the membranes herein are useful in filtering applications where high sheer is applied to reduce fouling



FIG. 4E illustrates pores formed using focused ion beam drilling where the average pore dimension is 20 nm. Few-layer graphene (up to about 20 graphene layers) can also be used in various embodiments of the present disclosure. Exemplary dimensions of the apertures in the graphene can be about 30 nm or less in size, 20 nm or less in size 10 nm or less in size, 7 nm or less in size, 5 nm or less in size, about 2 nm or less in size, or about 1 nm or less in size.


In accordance with the disclosure, a perforated graphene membrane mounted on a suitable bio-compatible support structure can be configured, for example, in a two chamber cross-flow vessel in a similar manner to today's polymer hemodialysis membranes. FIG. 5 shows an illustrative hemodialysis system containing a graphene-based membrane within a two-chamber cross-flow vessel. In this exemplary configuration (50), a two-chamber crossflow vessel (51) having a first chamber (52) for flow of draw solution (e.g., dialysate) and a second chamber (53) for flow of blood is provided with a selectively perforated membrane of graphene-based material (55). A planar or flat sheet membrane configuration is shown. It will be appreciated that alternative membrane configurations can be employed, such as spiral wound membrane configuration. In the membrane (55), the perforated graphene material is supported on a biocompatible porous polymer. The membrane is appropriately mounted and sealed within the vessel (51) employing any conventional method that provides an appropriate leak-proof seal. For example, the membrane can be mounted between two biocompatible mating frames with appropriate biocompatible gaskets. Alternatively, the membrane can be mounted and sealed using a biocompatible adhesive.


In general, contaminated blood entering via conduit 56 moves across a first surface of the graphene membrane (55), controlled transport channels in its surface (nominally 1 atom thick and defined by the pore sizes of the perforations) allow a high flow rate of contaminants to be removed very efficiently from the blood and transported across the membrane into the other side of the chamber (52) where a suitable draw solution (such as a dialysate) entering via conduit 58, solubilizes or entrains the contaminants and carries them away for disposal via conduit 59. Cleaned blood exits the system via conduit 57 and as shown in FIG. 1 can be returned to the patient via an intervening air trap. Multi-layer perforated graphene material as well as other two-dimensional materials can be used in a similar manner. Dialysate is passed through the system employing a pump (60). A blood pump (not shown) can be used (as illustrated in FIG. 1) for passage of blood through chamber 53. Flow pressure in the system can be monitored as illustrated in FIG. 1. A fresh dialysate receptacle (61) and a waste dialysate receptacle can be provided (62).


In a related multi-pass configuration, used dialysate exiting via conduit 59 can in whole or in part be transferred via conduit 65 to be mixed with fresh dialysate for recirculation through the system. Recirculation of dialysate decreases the volume of dialysate needed. In an embodiment in a multi-pass configuration, the used dialysate, such as that exiting via conduit 59 can be filtered using a membrane as described herein having selected pore size to remove/reduce the levels of undesired contaminant in the used dialysate.


It is known in the art of hemodialysis that it can be important to employ dialysate with minimum undesired components. Thus filtering devices employing membranes of this disclosure which comprises selectively perforated two-dimensional materials, such as graphene, can also be employed in the preparation of dialysate or be employed to pre-filter dialysate prior to introduction into a dialyzer.


Alternate fluidic arrangements that optimize the transformational transport across the graphene membrane can also be used. Another embodiment with a sequence of concatenated filter chambers can alleviate the need for a diffusively active draw solution.


Regardless of the utilized membrane configuration, as a direct result of the increased transport efficiency, the patient treatment time can be greatly reduced, the level of currently infused anti-coagulants (such as heparin) can be greatly reduced because of the graphene surface neutrality and smoothness (minimizing stirring and agitation that can trigger the clotting sequence), and the rate of auxiliary metabolite removal can be carefully controlled so as to minimize depletion of beneficial electrolytes with simultaneous removal of undesired contaminants. Use of the membranes of this disclosure has the potential to decrease complement activation which can lead to allergic reactions during treatment and may also lead to acute intradialytic pulmonary hypertension, chronic low-grade systemic inflammation and leukocyte dysfunction.


In some embodiments, the graphene or other two-dimensional material can be functionalized. Particularly, the perimeter of the apertures within the graphene can be functionalized. Suitable techniques for functionalizing graphene will be familiar to one having ordinary skill in the art. Moreover, given the benefit of the present disclosure and an understanding consistent with one having ordinary skill in the art, a skilled artisan will be able to choose a suitable functionality for producing a desired interaction with an entity in a fluid, such as a biological fluid. For example, the apertures in a graphene can be functionalized such that they interact preferentially with a protein or class of proteins in deference to other biological entities of similar size, thereby allowing separations based upon chemical characteristics to take place. In some embodiments, pores of a given two-dimensional material are functionalized with a chemical species that is positively charge at physiologic pH (e. g., carries one or more amine groups). In some embodiments, pores of a given two-dimensional material are functionalized with a chemical species that is positively negatively charged at physiologic pH (e. g., carries one or more carboxyl or sulfonate groups). In some embodiments, pores of a given two-dimensional material are functionalized with a chemical species that is hydrophobic and in other embodiments pores of a given two-dimensional material are functionalized with a chemical species that is hydrophilic.


In some embodiments, the graphene or other two-dimensional material can be functionalized with a chemical entity so that the functionalization interacts preferentially with a particular type of biological entity (e.g., by a chemical interaction). In some or other embodiments, the graphene or other two-dimensional material can be functionalized such that it interacts electrically with a biological entity (e.g., by a preferential electrostatic interaction). Selective interactions based upon biological recognition are also possible.


Membranes herein include a perforated two-dimensional material supported on a porous substrate. The porous material is preferably biocompatible and in some embodiments is preferably suitable for implantation in a human or animal body. The porous substrate can be a polymer, ceramic or metal. Suitable materials include among others, poly(methyl methacrylate) (PMMA), polyesters, polyamides, polyimides, polyethylene, polypropylene, polytetrafluoroethylene (PTFE), polyvinylidene fluoride (PVDF), polycarbonate, polyetherether-ketone polymers, i.e., PEEK™ polymers (Trademark Victrex, USA, Inc.) and particularly polyaryletheretherketone, polyvinyl chloride (PVC), and mixtures, copolymers and block copolymers thereof. Additionally, non-polymeric substrates such as Si, SiN, anodized alumina, porous ceramics, or sintered metals can be employed. In specific embodiments, the substrate is a biocompatible polymer. In an embodiment, suitable polymers for forming a porous or permeable fibrous layer are biocompatible, bioinert and/or medical grade materials. In specific embodiments, the substrate is a track-etched polymer. In specific embodiments, the substrate is track-etched polycarbonate.


In an embodiment, the support can itself have a porous structure wherein the pores are larger than those of the two-dimensional material. In an embodiment, the support structure is entirely porous. In embodiments, the support structure is at least in part non-porous.


In embodiments herein the two-dimensional material is a graphene-based material. In embodiments of herein, the two-dimensional material is graphene.


In embodiments herein at least a portion of the holes in the two-dimensional materials of the membranes are functionalized.


In embodiments herein at least a portion of the two-dimensional material is conductive and a voltage can be applied to at least a portion of the conductive two-dimensional material. The voltage can be an AC or DC voltage. The voltage can be applied from a source external to the membrane. In an embodiment, a membrane herein further comprises connectors and leads for application of a voltage from an external source to the two-dimensional material. Application of an electrical charge to a conductive membrane herein can additionally facilitate selective or targeted removal of components from blood, dialysate, and/or water. Additionally, the conductive properties of graphene-based or other two-dimensional membranes can allow for electrification to take place from an external source. In exemplary embodiments, an AC or DC voltage can be applied to conductive two-dimensional materials of the enclosure. The conductivity properties of graphene-based materials and graphene can provide additional gating to charged molecules. Electrification can occur permanently or only for a portion of the time to affect gating. Directional gating of charged molecules can be directed not only through the pores (or restrict travel through pores), but also to the surface of the graphene to adsorb or bind


Membranes herein can also be employed in blood filtration applications. In such applications, blood is passed through one or more or preferably two or more membranes in sequence to selectively remove components from the blood by size. For a membrane of given pore dimension, components of sufficiently smaller dimension compared to the pores will pass through the pores of the membrane while components of sufficiently larger dimension compared to the pores will not. Thus, filtration of selected blood components can be accomplished by passage of the blood through one or more membranes with selected pore dimensions.


An exemplary filtration configuration is illustrated in FIG. 6. In this configuration, blood is passed sequentially through a plurality of membranes at least two of which have different pore dimensions or pore densities. Preferably, at least two of the plurality of membranes have different pore dimensions. In the illustrated embodiment, six membranes are provided (71A-71F). Preferably, each of the membranes in the filtration configuration has different pore dimension. In a specific embodiment, the pore size dimension of the membranes decreases in the direction of blood flow. Passage of blood sequentially through the membranes generates flows (72A-72F are shown) which contain blood components separated by size. The separated flows can be individually collected, individually discarded or two or more of the flows can be combined for any appropriate use.


As discussed above, hemodialysis and hemofiltration are employed to remove toxic substances such as creatinine and urea from the blood typically to replace or supplement such function of the kidneys. The term “removed” is used herein to encompass a decrease in level of the component after dialysis or filtration. It is noted that the term removed includes decreasing the level of toxic species in the blood to non-toxic levels or to with the range of concentrations found in those whose individuals who have normal kidney function. During hemodialysis and hemofiltration, it is undesirable, as is known in the art, to remove or significantly lower the concentration of certain components below their normal concentration range in individuals with normal kidney function. One such component is serum albumin the removal of too much of which can be detrimental to an individual. It is generally known in the art which blood components should be removed and which should be retained to in general achieve component levels that are within the normal concentration level of the components in the blood. In some cases, hemodialysis and hemofiltration are performed continuously in an attempt to maintain levels of toxic species in the blood at concentrations the same as those in individuals with normal kidney function. In many cases however, hemodialysis and hemofiltration are performed intermittently (e.g., on a set schedule) to lower levels of toxic species in the blood to normal or below normal levels. During the time between treatments, the levels of toxic species can build up in the blood.


The membranes of this disclosure formed by introduction of pores of selective dimension into sheets or layers of two-dimensional material are particularly suited to targeted removal of components based on size. As illustrated in FIGS. 4A-4E, methods are available in the art for introduction of pores of different dimensions which allow for such targeted removal. For example, two-dimensional material having average pore dimension or size of 20 nm will allow passage of water, ions and most small molecules (molecular weight of 500 or less) and will also allow passage of many proteins. Two-dimensional materials having average pore size of 7 nm will allow a passage of water, ions and most small molecules (molecular weight of 500 or less), but will not allow passage of many protein species, such as serum albumin. Two-dimensional materials having average pore size of about 1 nm will allow passage of water and atomic ions generally, but will not allow passage of many molecular components. Choice of pore dimensions in a given membrane allows targeted removal of components from a liquid, such a blood.


Although the disclosure provided herein is primarily directed to hemodialysis membranes and blood filtration membranes formed from graphene materials it is to be recognized that graphene oxide (GO) and reduced graphene oxide (rGO) can also be used in alternative embodiments. It will be appreciated that filtration devices containing membranes and membranes herein may be prepared from combinations of two-dimensional materials. Other perforated two-dimensional materials can also be used as well. In addition to in vivo hemodialysis and hemofiltration techniques, ex vivo dialysis and filtration techniques are also contemplated as well.


Methods for treating a patient using the disclosed membranes are also contemplated herein. These treatment methods are performed using the disclosed membranes in a manner similar to that used with conventional hemodialysis or hemofiltration techniques. In brief, the methods involve contacting blood from a patient with a graphene-based hemodialysis or hemofiltration membrane (or membrane configuration, as illustrated in FIG. 6) in order to remove one or more contaminants therefrom. Contaminants removed from the blood by hemodialysis can then be removed in a dialysis fluid or those removed by filtration in a separated flow can be removed or collected as desired. The purified blood can then be recirculated to the patient. In an embodiment, hemodialysis methods herein are combined with blood filtration methods herein. In an embodiment, conventional hemodialysis methods herein are combined with blood filtration methods herein. Hemodialysis membranes and blood filtration membranes herein can also be employed in implantable devices, such as art-contemplated artificial kidneys and bioartifical kidneys.


The membranes herein can further be employed for peritoneal dialysis and in renal assist devices. Peritoneal dialysis is also employed to remove waste products from blood when normal kidney function is lost or impaired. Blood vessels in the abdominal lining (the peritoneum) replace the function of the kidneys when a dialysate is flowed into and out of the peritoneal space. Membranes herein can be employed for filtration of dialysate in peritoneal dialysis. Renal assist devices include wearable and implantable devices for hemodialysis and peritoneal dialysis. Membranes herein can be employed to implement such devices as dialysis membranes and/or filtration devices. Certain renal assist devices (e.g., bioartifical kidneys) include biological cells for carrying out certain metabolic functions. For example, an implantable artificial kidney can include a bio-cartridge of renal tubule cells which, mimic the metabolic and water-balance function of the kidneys. Two-dimensional materials, particularly graphene-based materials can be employed as selectively permeable enclosures to retain such cells and to allow selective entry of components into the enclosure and selective exit of components from the enclosure. Such enclosures can for example be employed in artificial kidney which contain a bio-cartridge. Such enclosure are described for example in U.S. application Ser. No. 14/656,190, filed, which is incorporated by reference herein in its entirety for descriptions of such enclosures.


Ex vivo dialysis techniques can be conducted similarly. Such dialysis techniques can be conducted upon a biological fluid, such as blood, or upon other dialyzable fluids in need of contaminant removal therefrom.


Although the disclosure has been described with reference to the disclosed embodiments, one having ordinary skill in the art will readily appreciate that these are only illustrative of the disclosure. It should be understood that various modifications can be made without departing from the spirit of the disclosure. The disclosure can be modified to incorporate any number of variations, alterations, substitutions or equivalent arrangements not heretofore described, but which are commensurate with the spirit and scope of the disclosure. Additionally, while various embodiments of the invention have been described, it is to be understood that aspects of the disclosure may include only some of the described embodiments. Accordingly, the disclosure is not to be seen as limited by the foregoing description.


Every formulation or combination of components described or exemplified can be used to practice the invention, unless otherwise stated. Specific names of compounds are intended to be exemplary, as it is known that one of ordinary skill in the art can name the same compounds differently. When a compound is described herein such that a particular isomer or enantiomer of the compound is not specified, for example, in a formula or in a chemical name, that description is intended to include each isomer and enantiomer of the compound described individually or in any combination. One of ordinary skill in the art will appreciate that methods, device elements, starting materials and synthetic methods other than those specifically exemplified can be employed in the practice of the invention without resort to undue experimentation. All art-known functional equivalents, of any such methods, device elements, starting materials and synthetic methods are intended to be included in this invention. Whenever a range is given in the specification, for example, a temperature range, a time range, or a composition range, all intermediate ranges and subranges, as well as all individual values included in the ranges given are intended to be included in the disclosure. When a Markush group or other grouping is used herein, all individual members of the group and all combinations and subcombinations possible of the group are intended to be individually included in the disclosure.


As used herein, “comprising” is synonymous with “including,” “containing,” or “characterized by,” and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. As used herein, “consisting of” excludes any element, step, or ingredient not specified in the claim element. As used herein, “consisting essentially of” does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim. Any recitation herein of the term “comprising”, particularly in a description of components of a composition or in a description of elements of a device, is understood to encompass those compositions and methods consisting essentially of and consisting of the recited components or elements. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein.


The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.


In general the terms and phrases used herein have their art-recognized meaning, which can be found by reference to standard texts, journal references and contexts known to those skilled in the art. The preceding definitions are provided to clarify their specific use in the context of the invention.


All references throughout this application, for example patent documents including issued or granted patents or equivalents; patent application publications; and non-patent literature documents or other source material; are hereby incorporated by reference herein in their entireties, as though individually incorporated by reference, to the extent each reference is at least partially not inconsistent with the disclosure in this application (for example, a reference that is partially inconsistent is incorporated by reference except for the partially inconsistent portion of the reference).


All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. References cited herein are incorporated by reference herein in their entirety to indicate the state of the art, in some cases as of their filing date, and it is intended that this information can be employed herein, if needed, to exclude (for example, to disclaim) specific embodiments that are in the prior art. For example, when a compound is claimed, it should be understood that compounds known in the prior art, including certain compounds disclosed in the references disclosed herein (particularly in referenced patent documents), are not intended to be included in the claims.

Claims
  • 1. A medical device comprising: an enclosure comprising a blood filtration membrane, wherein the blood filtration membrane comprises a perforated two-dimensional material comprising perforated graphene, the perforated two-dimensional material being disposed upon a porous support structure, andrenal tubule cells disposed within the enclosure;wherein: the perforated graphene is configured to retain the renal tubule cells; andthe perforated graphene is configured to allow selective entry and/or exit of at least one component contained in blood into and/or out of the enclosure.
  • 2. The medical device of claim 1, wherein the perforated two-dimensional material is graphene-based material.
  • 3. The medical device of claim 2, wherein the graphene-based material is single-layer graphene.
  • 4. The medical device of claim 1, wherein the perforated two-dimensional material is graphene oxide.
  • 5. A method comprising: exposing blood to a blood filtration device, the blood filtration device comprising: an enclosure comprising a blood filtration membrane, wherein the blood filtration membrane comprises a perforated two-dimensional material comprising perforated graphene, the perforated two-dimensional material being disposed upon a porous support structure, andrenal tubule cells disposed within the enclosure;wherein: the perforated graphene is configured to retain the renal tubule cells; andthe perforated graphene is configured to allow selective entry and/or exit of at least one component contained in blood into and/or out of the enclosure.
  • 6. The method of claim 5, wherein the perforated two-dimensional material is graphene-based material.
  • 7. The method of claim 6, wherein the graphene-based material is single-layer graphene.
  • 8. The method of claim 5, wherein the perforated two-dimensional material is graphene oxide.
  • 9. The medical device of claim 1, wherein: the perforated graphene is configured to deny selective entry of at least one component contained in blood into the enclosure; andthe at least one component denied entry comprises one or more proteins.
  • 10. The method of claim 5, further comprising implanting the blood filtration membrane into a subject in need thereof.
  • 11. The method of claim 10, wherein the subject is a diabetic subject.
  • 12. The method of claim 10, wherein the method is a method of treating diabetes.
  • 13. The medical device of claim 1, wherein the porous structure comprises a biocompatible polymer selected from the group of poly(methyl methacrylate) (PMMA), polyesters, polyamides, polyimides, polyethylene, polypropylene, polytetrafluoroethylene (PTFE), polyvinylidene fluoride (PVDF), polycarbonate, polyetherether-ketone polymers, polyaryletheretherketone, polyvinyl chloride (PVC), and mixtures, copolymers or block copolymers thereof.
  • 14. The medical device of claim 1, wherein the at least one component contained in blood comprises a waste product.
  • 15. The medical device of claim 14, wherein the waste product comprises urea.
  • 16. The medical device of claim 9, wherein the one or more proteins comprise albumin.
  • 17. The medical device of claim 1, wherein the medical device is a bioartificial kidney.
  • 18. The method of claim 5, wherein the at least one component contained in blood comprises a waste product and the waste product comprises urea.
  • 19. The method of claim 5, wherein when the blood filtration membrane is contacted with blood at least one component contained in the blood is denied selective entry into the device; and the at least one component denied entry comprises one or more proteins.
  • 20. A blood filtration device comprising: an enclosure comprising a blood filtration membrane, wherein the blood filtration membrane comprises at least one layer of a perforated two-dimensional graphene, the perforated two-dimensional material being disposed upon a porous support structure, andrenal tubule cells disposed within the enclosure;wherein: the perforated graphene comprises apertures about 30 nm or less in size.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. provisional application 62/044,877, filed Sep. 2, 2014, which is incorporated by reference herein in its entirety.

US Referenced Citations (616)
Number Name Date Kind
2187417 Doble Jan 1940 A
3024153 Kennedy Mar 1962 A
3303085 Price et al. Feb 1967 A
3501831 Gordon Mar 1970 A
3593854 Swank Jul 1971 A
3701433 Krakauer et al. Oct 1972 A
3802972 Fleischer et al. Apr 1974 A
4073732 Lauer et al. Feb 1978 A
4159954 Gangemi Jul 1979 A
4162220 Servas Jul 1979 A
4277344 Cadotte Jul 1981 A
4303530 Shah Dec 1981 A
4743371 Servas et al. May 1988 A
4855058 Holland et al. Aug 1989 A
4880440 Perrin Nov 1989 A
4889626 Browne Dec 1989 A
4891134 Vcelka Jan 1990 A
4925560 Sorrick May 1990 A
4935207 Stanbro et al. Jun 1990 A
4976858 Kadoya Dec 1990 A
5052444 Messerly et al. Oct 1991 A
5080770 Culkin Jan 1992 A
5082476 Kahlbaugh et al. Jan 1992 A
5156628 Kranz Oct 1992 A
5182111 Aebischer et al. Jan 1993 A
5185086 Kaali et al. Feb 1993 A
5201767 Caldarise et al. Apr 1993 A
5244981 Seidner et al. Sep 1993 A
5314492 Hamilton et al. May 1994 A
5314960 Spinelli et al. May 1994 A
5314961 Anton et al. May 1994 A
5331067 Seidner et al. Jul 1994 A
5344454 Clarke et al. Sep 1994 A
5371147 Spinelli et al. Dec 1994 A
5425858 Farmer Jun 1995 A
5480449 Hamilton et al. Jan 1996 A
5514181 Light et al. May 1996 A
5516522 Peyman et al. May 1996 A
5549697 Caldarise Aug 1996 A
5562944 Kafrawy Oct 1996 A
5565210 Rosenthal et al. Oct 1996 A
5580530 Kowatsch et al. Dec 1996 A
5595621 Light et al. Jan 1997 A
5636437 Kaschmitter et al. Jun 1997 A
5639275 Baetge et al. Jun 1997 A
5641323 Caldarise Jun 1997 A
5658334 Caldarise et al. Aug 1997 A
5662158 Caldarise Sep 1997 A
5665118 LaSalle et al. Sep 1997 A
5671897 Ogg et al. Sep 1997 A
5679232 Fedor et al. Oct 1997 A
5679249 Fendya et al. Oct 1997 A
5687788 Caldarise et al. Nov 1997 A
5700477 Rosenthal et al. Dec 1997 A
5713410 LaSalle et al. Feb 1998 A
5716412 DeCarlo et al. Feb 1998 A
5716414 Caldarise Feb 1998 A
5725586 Sommerich Mar 1998 A
5731360 Pekala et al. Mar 1998 A
5733503 Kowatsch et al. Mar 1998 A
5746272 Mastrorio et al. May 1998 A
5782286 Sommerich Jul 1998 A
5782289 Mastrorio et al. Jul 1998 A
5788916 Caldarise Aug 1998 A
5800828 Dionne et al. Sep 1998 A
5808312 Fukuda Sep 1998 A
5868727 Barr et al. Feb 1999 A
5897592 Caldarise et al. Apr 1999 A
5902762 Mercuri et al. May 1999 A
5906234 Mastrorio et al. May 1999 A
5910172 Penenberg Jun 1999 A
5910173 DeCarlo et al. Jun 1999 A
5913998 Butler et al. Jun 1999 A
5922304 Unger Jul 1999 A
5925247 Huebbel Jul 1999 A
5932185 Pekala et al. Aug 1999 A
5935084 Southworth Aug 1999 A
5935172 Ochoa et al. Aug 1999 A
5954937 Farmer Sep 1999 A
5974973 Tittgemeyer Nov 1999 A
5976555 Liu et al. Nov 1999 A
5980718 Van Konynenburg et al. Nov 1999 A
6008431 Caldarise et al. Dec 1999 A
6013080 Khalili Jan 2000 A
6022509 Matthews et al. Feb 2000 A
6052608 Young et al. Apr 2000 A
6080393 Liu et al. Jun 2000 A
6093209 Sanders Jul 2000 A
6139585 Li Oct 2000 A
6152882 Prutchi Nov 2000 A
6156323 Verdicchio et al. Dec 2000 A
6193956 Liu et al. Feb 2001 B1
6209621 Treacy Apr 2001 B1
6213124 Butterworth Apr 2001 B1
6228123 Dezzani May 2001 B1
6264699 Noiles et al. Jul 2001 B1
6292704 Malonek et al. Sep 2001 B1
6309532 Tran et al. Oct 2001 B1
6346187 Tran et al. Feb 2002 B1
6375014 Garcera et al. Apr 2002 B1
6426214 Butler et al. Jul 2002 B1
6454095 Brisebois et al. Sep 2002 B1
6455115 Demeyer Sep 2002 B1
6461622 Liu et al. Oct 2002 B2
6462935 Shiue et al. Oct 2002 B1
6521865 Jones et al. Feb 2003 B1
6532386 Sun et al. Mar 2003 B2
6544316 Baker et al. Apr 2003 B2
6580598 Shiue et al. Jun 2003 B2
6654229 Yanagisawa et al. Nov 2003 B2
6659298 Wong Dec 2003 B2
6660150 Conlan et al. Dec 2003 B2
6661643 Shiue et al. Dec 2003 B2
6686437 Buchman et al. Feb 2004 B2
6692627 Russell et al. Feb 2004 B1
6695880 Roffman et al. Feb 2004 B1
6699684 Ho et al. Mar 2004 B2
6719740 Burnett et al. Apr 2004 B2
6905612 Dorian et al. Jun 2005 B2
6924190 Dennison Aug 2005 B2
7014829 Yanagisawa et al. Mar 2006 B2
7071406 Smalley et al. Jul 2006 B2
7092753 Darvish et al. Aug 2006 B2
7138042 Tran et al. Nov 2006 B2
7171263 Darvish et al. Jan 2007 B2
7175783 Curran Feb 2007 B2
7179419 Lin et al. Feb 2007 B2
7190997 Darvish et al. Mar 2007 B1
7267753 Anex et al. Sep 2007 B2
7306768 Chiga Dec 2007 B2
7357255 Ginsberg et al. Apr 2008 B2
7374677 McLaughlin et al. May 2008 B2
7381707 Lin et al. Jun 2008 B2
7382601 Yoshimitsu Jun 2008 B2
7434692 Ginsberg et al. Oct 2008 B2
7452547 Lambino et al. Nov 2008 B2
7459121 Liang et al. Dec 2008 B2
7460907 Darvish et al. Dec 2008 B1
7476222 Sun et al. Jan 2009 B2
7477939 Sun et al. Jan 2009 B2
7477940 Sun et al. Jan 2009 B2
7477941 Sun et al. Jan 2009 B2
7479133 Sun et al. Jan 2009 B2
7505250 Cho et al. Mar 2009 B2
7531094 McLaughlin et al. May 2009 B2
7600567 Christopher et al. Oct 2009 B2
7631764 Ginsberg et al. Dec 2009 B2
7650805 Nauseda et al. Jan 2010 B2
7674477 Schmid et al. Mar 2010 B1
7706128 Bourcier Apr 2010 B2
7761809 Bukovec et al. Jul 2010 B2
7786086 Reches et al. Aug 2010 B2
7866475 Doskoczynski et al. Jan 2011 B2
7875293 Shults et al. Jan 2011 B2
7935331 Lin May 2011 B2
7935416 Yang et al. May 2011 B2
7943167 Kulkarni et al. May 2011 B2
7960708 Wolfe et al. Jun 2011 B2
7998246 Liu et al. Aug 2011 B2
8109893 Lande Feb 2012 B2
8147599 McAlister Apr 2012 B2
8262943 Meng et al. Sep 2012 B2
8278106 Martinson et al. Oct 2012 B2
8308702 Batchvarova et al. Nov 2012 B2
8316865 Ochs et al. Nov 2012 B2
8329476 Pitkanen et al. Dec 2012 B2
8354296 Dimitrakopoulos et al. Jan 2013 B2
8361321 Stetson et al. Jan 2013 B2
8449504 Carter et al. May 2013 B2
8475689 Sun et al. Jul 2013 B2
8506807 Lee et al. Aug 2013 B2
8512669 Hauck Aug 2013 B2
8513324 Scales et al. Aug 2013 B2
8535726 Dai et al. Sep 2013 B2
8592291 Shi et al. Nov 2013 B2
8617411 Singh Dec 2013 B2
8666471 Rogers et al. Mar 2014 B2
8686249 Whitaker et al. Apr 2014 B1
8697230 Ago et al. Apr 2014 B2
8698481 Lieber et al. Apr 2014 B2
8715329 Robinson et al. May 2014 B2
8721074 Pugh et al. May 2014 B2
8734421 Sun et al. May 2014 B2
8744567 Fassih et al. Jun 2014 B2
8751015 Frewin et al. Jun 2014 B2
8753468 Caldwell et al. Jun 2014 B2
8759153 Elian et al. Jun 2014 B2
8808257 Pugh et al. Aug 2014 B2
8828211 Garaj et al. Sep 2014 B2
8840552 Brauker et al. Sep 2014 B2
8857983 Pugh et al. Oct 2014 B2
8861821 Osumi Oct 2014 B2
8894201 Pugh et al. Nov 2014 B2
8940552 Pugh et al. Jan 2015 B2
8950862 Pugh et al. Feb 2015 B2
8974055 Pugh et al. Mar 2015 B2
8975121 Pugh et al. Mar 2015 B2
8979978 Miller et al. Mar 2015 B2
8986932 Turner et al. Mar 2015 B2
8993234 Turner et al. Mar 2015 B2
8993327 McKnight et al. Mar 2015 B2
9014639 Pugh et al. Apr 2015 B2
9017937 Turner et al. Apr 2015 B1
9023220 Graphenea May 2015 B2
9028663 Stetson et al. May 2015 B2
9035282 Dimitrakopoulos et al. May 2015 B2
9045847 Batchvarova et al. Jun 2015 B2
9050452 Sun et al. Jun 2015 B2
9052533 Pugh et al. Jun 2015 B2
9056282 Miller et al. Jun 2015 B2
9062180 Scales et al. Jun 2015 B2
9067811 Bennett et al. Jun 2015 B1
9070615 Elian et al. Jun 2015 B2
9075009 Kim et al. Jul 2015 B2
9080267 Batchvarova et al. Jul 2015 B2
9095823 Fleming Aug 2015 B2
9096050 Bedell et al. Aug 2015 B2
9096437 Tour et al. Aug 2015 B2
9102111 Pugh et al. Aug 2015 B2
9108158 Yu et al. Aug 2015 B2
9110310 Pugh et al. Aug 2015 B2
9125715 Pugh et al. Sep 2015 B2
9134546 Pugh et al. Sep 2015 B2
9169575 Bedworth et al. Oct 2015 B1
9170646 Toner et al. Oct 2015 B2
9185486 Pugh Nov 2015 B2
9193587 Bennett Nov 2015 B2
9195075 Pugh et al. Nov 2015 B2
9225375 Pugh et al. Dec 2015 B2
9242865 Sinton et al. Jan 2016 B2
9388048 Zhou et al. Jul 2016 B1
9425709 Hayashi et al. Aug 2016 B2
9437370 Chen et al. Sep 2016 B2
9463421 Fleming Oct 2016 B2
9475709 Stetson et al. Oct 2016 B2
9480952 Sinton et al. Nov 2016 B2
9505192 Stoltenberg et al. Nov 2016 B2
9567224 Bedworth Feb 2017 B2
9572918 Bachmann et al. Feb 2017 B2
9592475 Stoltenberg et al. Mar 2017 B2
9610546 Sinton et al. Apr 2017 B2
9708640 Wu et al. Jul 2017 B2
9713794 Choi et al. Jul 2017 B2
9870895 Bedworth Jan 2018 B2
20010036556 Jen Nov 2001 A1
20010047157 Burnett et al. Nov 2001 A1
20010055597 Liu et al. Dec 2001 A1
20020079004 Sato et al. Jun 2002 A1
20020079054 Nakatani Jun 2002 A1
20020104435 Baker et al. Aug 2002 A1
20020115957 Sun et al. Aug 2002 A1
20020117659 Lieber et al. Aug 2002 A1
20020183682 Darvish et al. Dec 2002 A1
20020183686 Darvish et al. Dec 2002 A1
20030052354 Dennison Mar 2003 A1
20030134281 Evans Jul 2003 A1
20030138777 Evans Jul 2003 A1
20030146221 Lauer et al. Aug 2003 A1
20030159985 Siwy et al. Aug 2003 A1
20040035787 Tanga et al. Feb 2004 A1
20040061253 Kleinmeyer et al. Apr 2004 A1
20040063097 Evans Apr 2004 A1
20040099324 Fraser et al. May 2004 A1
20040111968 Day et al. Jun 2004 A1
20040112865 McCullough et al. Jun 2004 A1
20040121488 Chang et al. Jun 2004 A1
20040142463 Walker et al. Jul 2004 A1
20040185730 Lambino et al. Sep 2004 A1
20040193043 Duchon et al. Sep 2004 A1
20040199243 Yodfat Oct 2004 A1
20040217036 Ginsberg et al. Nov 2004 A1
20040241214 Kirkwood et al. Dec 2004 A1
20040251136 Lean et al. Dec 2004 A1
20050004508 Sun et al. Jan 2005 A1
20050004509 Sun et al. Jan 2005 A1
20050004550 Sun et al. Jan 2005 A1
20050010161 Sun et al. Jan 2005 A1
20050010192 Sun et al. Jan 2005 A1
20050015042 Sun et al. Jan 2005 A1
20050053563 Manissier et al. Mar 2005 A1
20050112078 Boddupalli et al. May 2005 A1
20050126966 Tanida et al. Jun 2005 A1
20050129633 Lin Jun 2005 A1
20050148996 Sun et al. Jul 2005 A1
20050170089 Lashmore et al. Aug 2005 A1
20050189673 Klug et al. Sep 2005 A1
20050226834 Lambino et al. Oct 2005 A1
20050238730 Le Fur et al. Oct 2005 A1
20060005381 Nishi et al. Jan 2006 A1
20060036332 Jennings Feb 2006 A1
20060073370 Krusic et al. Apr 2006 A1
20060093885 Krusic et al. May 2006 A1
20060121279 Petrik Jun 2006 A1
20060151382 Petrik Jul 2006 A1
20060166347 Faulstich et al. Jul 2006 A1
20060180604 Ginsberg et al. Aug 2006 A1
20060222701 Kulkarni et al. Oct 2006 A1
20060253078 Wu et al. Nov 2006 A1
20070004640 Lin et al. Jan 2007 A1
20070032054 Ramaswamy et al. Feb 2007 A1
20070056894 Connors, Jr. Mar 2007 A1
20070060862 Sun et al. Mar 2007 A1
20070062856 Pahl et al. Mar 2007 A1
20070099813 Luizzi et al. May 2007 A1
20070131646 Donnelly et al. Jun 2007 A1
20070284279 Doskoczynski et al. Dec 2007 A1
20080017564 Hammond Jan 2008 A1
20080035484 Wu et al. Feb 2008 A1
20080035541 Franzreb et al. Feb 2008 A1
20080045877 Levin et al. Feb 2008 A1
20080061477 Capizzo Mar 2008 A1
20080063585 Smalley et al. Mar 2008 A1
20080081323 Keeley et al. Apr 2008 A1
20080081362 Keeley et al. Apr 2008 A1
20080149561 Chu et al. Jun 2008 A1
20080156648 Dudziak et al. Jul 2008 A1
20080170982 Zhang et al. Jul 2008 A1
20080185293 Klose et al. Aug 2008 A1
20080188836 Weber et al. Aug 2008 A1
20080190508 Booth et al. Aug 2008 A1
20080241085 Lin et al. Oct 2008 A1
20080268016 Fang et al. Oct 2008 A1
20080290020 Marand et al. Nov 2008 A1
20080290111 Ginsberg et al. Nov 2008 A1
20090023572 Backes et al. Jan 2009 A1
20090032475 Ferrer et al. Feb 2009 A1
20090039019 Raman Feb 2009 A1
20090048685 Frigstad et al. Feb 2009 A1
20090075371 Keeley et al. Mar 2009 A1
20090078640 Chu et al. Mar 2009 A1
20090087395 Lin et al. Apr 2009 A1
20090117335 Iyoda et al. May 2009 A1
20090148495 Hammer et al. Jun 2009 A1
20090176159 Zhamu et al. Jul 2009 A1
20090222072 Robinson et al. Sep 2009 A1
20090236295 Braun et al. Sep 2009 A1
20090241242 Beatty et al. Oct 2009 A1
20090283475 Hylton et al. Nov 2009 A1
20090291270 Zettl et al. Nov 2009 A1
20090294300 Kanzius et al. Dec 2009 A1
20090306364 Beer et al. Dec 2009 A1
20100000754 Mann et al. Jan 2010 A1
20100016778 Chattopadhyay Jan 2010 A1
20100021708 Kong et al. Jan 2010 A1
20100024722 Ochs et al. Feb 2010 A1
20100024838 Ochs et al. Feb 2010 A1
20100025330 Ratto et al. Feb 2010 A1
20100055464 Sung Mar 2010 A1
20100059378 Elson et al. Mar 2010 A1
20100072643 Pugh et al. Mar 2010 A1
20100076553 Pugh et al. Mar 2010 A1
20100105834 Tour et al. Apr 2010 A1
20100110372 Pugh et al. May 2010 A1
20100124564 Martinson et al. May 2010 A1
20100127312 Grebel et al. May 2010 A1
20100161014 Lynch et al. Jun 2010 A1
20100167551 Dedontney Jul 2010 A1
20100196439 Beck et al. Aug 2010 A1
20100209330 Golzhauser et al. Aug 2010 A1
20100209515 Chantalat et al. Aug 2010 A1
20100213079 Willis Aug 2010 A1
20100224555 Hoek et al. Sep 2010 A1
20100228204 Beatty et al. Sep 2010 A1
20100233781 Bangera et al. Sep 2010 A1
20100249273 Scales et al. Sep 2010 A1
20100258111 Shah et al. Oct 2010 A1
20100323177 Ruoff et al. Dec 2010 A1
20100327847 Leiber et al. Dec 2010 A1
20110014217 Fahmy et al. Jan 2011 A1
20110037033 Green et al. Feb 2011 A1
20110041519 McAlister Feb 2011 A1
20110041687 Diaz et al. Feb 2011 A1
20110045523 Strano et al. Feb 2011 A1
20110054418 Pugh et al. Mar 2011 A1
20110054576 Robinson et al. Mar 2011 A1
20110056892 Lancaster Mar 2011 A1
20110073563 Chang et al. Mar 2011 A1
20110092054 Seo et al. Apr 2011 A1
20110092949 Wang Apr 2011 A1
20110100921 Heinrich May 2011 A1
20110112484 Carter et al. May 2011 A1
20110118655 Fassih et al. May 2011 A1
20110120970 Joo et al. May 2011 A1
20110124253 Shah et al. May 2011 A1
20110132834 Tomioka et al. Jun 2011 A1
20110139707 Siwy et al. Jun 2011 A1
20110152795 Aledo et al. Jun 2011 A1
20110201201 Arnold et al. Aug 2011 A1
20110202201 Matsubara Aug 2011 A1
20110253630 Bakajin et al. Oct 2011 A1
20110258791 Batchvarova et al. Oct 2011 A1
20110258796 Batchvarova et al. Oct 2011 A1
20110262645 Batchvarova et al. Oct 2011 A1
20110263912 Miller et al. Oct 2011 A1
20110269920 Min et al. Nov 2011 A1
20120000845 Park et al. Jan 2012 A1
20120031833 Ho et al. Feb 2012 A1
20120048804 Stetson et al. Mar 2012 A1
20120115243 Pitkanen et al. May 2012 A1
20120116228 Okubo May 2012 A1
20120145548 Sivan et al. Jun 2012 A1
20120148633 Sun et al. Jun 2012 A1
20120162600 Pugh et al. Jun 2012 A1
20120183738 Zettl et al. Jul 2012 A1
20120186850 Sugiyama et al. Jul 2012 A1
20120211367 Vecitis Aug 2012 A1
20120218508 Pugh et al. Aug 2012 A1
20120220053 Lee et al. Aug 2012 A1
20120234453 Pugh et al. Sep 2012 A1
20120234679 Garaj et al. Sep 2012 A1
20120235277 Pugh et al. Sep 2012 A1
20120236254 Pugh et al. Sep 2012 A1
20120236524 Pugh et al. Sep 2012 A1
20120241371 Revanur et al. Sep 2012 A1
20120242953 Pugh et al. Sep 2012 A1
20120255899 Choi et al. Oct 2012 A1
20120267337 Striemer et al. Oct 2012 A1
20120292245 Saito Nov 2012 A1
20120298396 Hong et al. Nov 2012 A1
20120301707 Kinloch et al. Nov 2012 A1
20130015136 Bennett Jan 2013 A1
20130034760 Otts et al. Feb 2013 A1
20130045523 Leach et al. Feb 2013 A1
20130056367 Martinez et al. Mar 2013 A1
20130071941 Miller Mar 2013 A1
20130096292 Brahmasandra et al. Apr 2013 A1
20130100436 Jackson et al. Apr 2013 A1
20130105417 Stetson et al. May 2013 A1
20130108839 Arnold et al. May 2013 A1
20130116541 Gracias et al. May 2013 A1
20130131214 Scales et al. May 2013 A1
20130135578 Pugh et al. May 2013 A1
20130146221 Kolmakov et al. Jun 2013 A1
20130146480 Garaj et al. Jun 2013 A1
20130152386 Pandojirao-s et al. Jun 2013 A1
20130174978 Pugh et al. Jul 2013 A1
20130190476 Lancaster et al. Jul 2013 A1
20130192460 Miller et al. Aug 2013 A1
20130192461 Miller et al. Aug 2013 A1
20130194540 Pugh et al. Aug 2013 A1
20130213568 Pugh et al. Aug 2013 A1
20130215377 Pugh et al. Aug 2013 A1
20130215378 Pugh et al. Aug 2013 A1
20130215380 Pugh et al. Aug 2013 A1
20130216581 Fahmy et al. Aug 2013 A1
20130240355 Ho et al. Sep 2013 A1
20130240437 Rodrigues et al. Sep 2013 A1
20130248097 Ploss, Jr. Sep 2013 A1
20130248367 Stetson et al. Sep 2013 A1
20130249147 Bedworth Sep 2013 A1
20130256118 Meller et al. Oct 2013 A1
20130256139 Peng Oct 2013 A1
20130256154 Peng Oct 2013 A1
20130256210 Fleming Oct 2013 A1
20130256211 Fleming Oct 2013 A1
20130261568 Martinson et al. Oct 2013 A1
20130269819 Ruby et al. Oct 2013 A1
20130270188 Karnik et al. Oct 2013 A1
20130273288 Luo et al. Oct 2013 A1
20130277305 Stetson et al. Oct 2013 A1
20130295150 Chantalat et al. Nov 2013 A1
20130309776 Drndic et al. Nov 2013 A1
20130317131 Scales et al. Nov 2013 A1
20130317132 Scales et al. Nov 2013 A1
20130317133 Scales et al. Nov 2013 A1
20130323295 Scales et al. Dec 2013 A1
20130338611 Pugh et al. Dec 2013 A1
20130338744 Frewin et al. Dec 2013 A1
20140002788 Otts et al. Jan 2014 A1
20140005514 Pugh et al. Jan 2014 A1
20140015160 Kung et al. Jan 2014 A1
20140017322 Dai et al. Jan 2014 A1
20140048411 Choi et al. Feb 2014 A1
20140066958 Priewe Mar 2014 A1
20140079936 Russo et al. Mar 2014 A1
20140093728 Shah et al. Apr 2014 A1
20140128891 Astani-Matthies et al. May 2014 A1
20140141521 Peng et al. May 2014 A1
20140151288 Miller et al. Jun 2014 A1
20140151631 Duesberg et al. Jun 2014 A1
20140154464 Miller et al. Jun 2014 A1
20140170195 Fassih et al. Jun 2014 A1
20140171541 Scales et al. Jun 2014 A1
20140174927 Bashir et al. Jun 2014 A1
20140190004 Riall et al. Jul 2014 A1
20140190550 Loh et al. Jul 2014 A1
20140190676 Zhamu et al. Jul 2014 A1
20140190833 Lieber et al. Jul 2014 A1
20140192313 Riall et al. Jul 2014 A1
20140192314 Riall et al. Jul 2014 A1
20140199777 Ruiz et al. Jul 2014 A2
20140209539 El Badawi et al. Jul 2014 A1
20140212596 Jahangiri-Famenini Jul 2014 A1
20140230653 Yu et al. Aug 2014 A1
20140230733 Miller Aug 2014 A1
20140231351 Wickramasinghe et al. Aug 2014 A1
20140248621 Collins Sep 2014 A1
20140257348 Priewe et al. Sep 2014 A1
20140257515 So et al. Sep 2014 A1
20140257517 Deichmann et al. Sep 2014 A1
20140259657 Riall et al. Sep 2014 A1
20140261999 Stetson et al. Sep 2014 A1
20140263035 Stoltenberg et al. Sep 2014 A1
20140263178 Sinton et al. Sep 2014 A1
20140264977 Pugh et al. Sep 2014 A1
20140268015 Riall et al. Sep 2014 A1
20140268020 Pugh et al. Sep 2014 A1
20140268021 Pugh et al. Sep 2014 A1
20140268026 Pugh et al. Sep 2014 A1
20140272286 Stoltenberg et al. Sep 2014 A1
20140272522 Pugh et al. Sep 2014 A1
20140273315 Pugh et al. Sep 2014 A1
20140273316 Pugh et al. Sep 2014 A1
20140276481 Pugh et al. Sep 2014 A1
20140276999 Harms et al. Sep 2014 A1
20140306361 Pugh et al. Oct 2014 A1
20140308681 Strano et al. Oct 2014 A1
20140315213 Nagrath et al. Oct 2014 A1
20140318373 Wood et al. Oct 2014 A1
20140322518 Addleman et al. Oct 2014 A1
20140333892 Pugh et al. Nov 2014 A1
20140335661 Pugh et al. Nov 2014 A1
20140343580 Priewe Nov 2014 A1
20140346081 Sowden et al. Nov 2014 A1
20140349892 Van Der Zaag et al. Nov 2014 A1
20140350372 Pugh et al. Nov 2014 A1
20140377651 Kwon et al. Dec 2014 A1
20140377738 Bachmann et al. Dec 2014 A1
20150015843 Pugh et al. Jan 2015 A1
20150017918 Pugh et al. Jan 2015 A1
20150053627 Silin et al. Feb 2015 A1
20150057762 Harms et al. Feb 2015 A1
20150061990 Toner et al. Mar 2015 A1
20150062533 Toner et al. Mar 2015 A1
20150063605 Pugh Mar 2015 A1
20150066063 Priewe Mar 2015 A1
20150075667 McHugh et al. Mar 2015 A1
20150077658 Pugh et al. Mar 2015 A1
20150077659 Pugh et al. Mar 2015 A1
20150077660 Pugh et al. Mar 2015 A1
20150077661 Pugh et al. Mar 2015 A1
20150077662 Pugh et al. Mar 2015 A1
20150077663 Pugh et al. Mar 2015 A1
20150077699 De Sio et al. Mar 2015 A1
20150077702 Pugh et al. Mar 2015 A9
20150079683 Yager et al. Mar 2015 A1
20150087249 Pugh et al. Mar 2015 A1
20150096935 Mitra et al. Apr 2015 A1
20150098910 Mordas et al. Apr 2015 A1
20150101931 Garaj et al. Apr 2015 A1
20150105686 Vasan Apr 2015 A1
20150118318 Fahmy et al. Apr 2015 A1
20150122727 Karnik et al. May 2015 A1
20150138454 Pugh et al. May 2015 A1
20150142107 Pugh et al. May 2015 A1
20150145155 Pugh et al. May 2015 A1
20150146162 Pugh et al. May 2015 A1
20150147474 Batchvarova et al. May 2015 A1
20150170788 Miller et al. Jun 2015 A1
20150174253 Sun et al. Jun 2015 A1
20150174254 Sun et al. Jun 2015 A1
20150182473 Bosnyak et al. Jul 2015 A1
20150185180 Ruhl et al. Jul 2015 A1
20150196579 Ferrante et al. Jul 2015 A1
20150202351 Kaplan et al. Jul 2015 A1
20150212339 Pugh et al. Jul 2015 A1
20150217219 Sinsabaugh et al. Aug 2015 A1
20150218210 Stetson et al. Aug 2015 A1
20150221474 Bedworth Aug 2015 A1
20150231557 Miller et al. Aug 2015 A1
20150231577 Nair et al. Aug 2015 A1
20150247178 Mountcastle et al. Sep 2015 A1
20150258254 Simon et al. Sep 2015 A1
20150258498 Simon et al. Sep 2015 A1
20150258502 Turowski Sep 2015 A1
20150258503 Sinton et al. Sep 2015 A1
20150258525 Westman et al. Sep 2015 A1
20150268150 Newkirk et al. Sep 2015 A1
20150272834 Sun et al. Oct 2015 A1
20150272896 Sun et al. Oct 2015 A1
20150273401 Miller et al. Oct 2015 A1
20150309337 Flitsch et al. Oct 2015 A1
20150321147 Fleming et al. Nov 2015 A1
20150321149 McGinnis Nov 2015 A1
20150323811 Flitsch et al. Nov 2015 A1
20150336202 Bedworth et al. Nov 2015 A1
20150342900 Putnins Dec 2015 A1
20150346382 Bliven et al. Dec 2015 A1
20150351887 Peters Dec 2015 A1
20150359742 Fassih et al. Dec 2015 A1
20150378176 Flitsch et al. Dec 2015 A1
20160009049 Stoltenberg et al. Jan 2016 A1
20160038885 Hogen-Esch et al. Feb 2016 A1
20160043384 Zhamu et al. Feb 2016 A1
20160058932 Stetson et al. Mar 2016 A1
20160059190 Yoo et al. Mar 2016 A1
20160067390 Simon et al. Mar 2016 A1
20160074814 Park et al. Mar 2016 A1
20160074815 Sinton et al. Mar 2016 A1
20160256805 Grein et al. Sep 2016 A1
20160272499 Zurutuza Elorza et al. Sep 2016 A1
20160282326 Waduge et al. Sep 2016 A1
20160284811 Yu et al. Sep 2016 A1
20160339160 Bedworth et al. Nov 2016 A1
20170000937 Gottschalk Jan 2017 A1
20170032962 Zurutuza Elorza et al. Feb 2017 A1
20170035943 Simon et al. Feb 2017 A1
20170036916 Bedworth et al. Feb 2017 A1
20170037356 Simon et al. Feb 2017 A1
20170057812 Zurutuza Elorza et al. Mar 2017 A1
20170065939 Kim et al. Mar 2017 A1
20170202885 Agulnick Jul 2017 A1
20170239623 Stoltenberg et al. Aug 2017 A1
20170296972 Sinton et al. Oct 2017 A1
20170296976 Liu et al. Oct 2017 A1
20170296979 Swett et al. Oct 2017 A1
Foreign Referenced Citations (110)
Number Date Country
2037988 Sep 1992 CA
2411935 Dec 2002 CA
1128501 Aug 1996 CN
101108194 Jan 2008 CN
101243544 Aug 2008 CN
101428198 May 2009 CN
101489653 Jul 2009 CN
101996853 Mar 2011 CN
102242062 Nov 2011 CN
102344132 Feb 2012 CN
102423272 Apr 2012 CN
102592720 Jul 2012 CN
101996853 Aug 2012 CN
102637584 Aug 2012 CN
103153441 Jun 2013 CN
103182249 Jul 2013 CN
203235358 Oct 2013 CN
103480281 Jan 2014 CN
103585891 Feb 2014 CN
103603706 Feb 2014 CN
19536560 Mar 1997 DE
10 2005 049 388 Apr 2007 DE
0 364 628 Apr 1990 EP
1 034 251 Jan 2004 EP
1 777 250 Apr 2007 EP
1 872 812 Jan 2008 EP
2 060 286 May 2009 EP
2 107 120 Oct 2009 EP
2 230 511 Sep 2010 EP
1 603 609 May 2011 EP
2 354 272 Aug 2011 EP
2 450 096 May 2012 EP
2 489 520 Aug 2012 EP
2 511 002 Oct 2012 EP
2 586 473 May 2013 EP
2 679 540 Jan 2014 EP
2 937 313 Oct 2015 EP
3 070 053 Sep 2016 EP
3 084 398 Oct 2016 EP
1 538 2430.5 Mar 2017 EP
3 135 631 Mar 2017 EP
59-102111 Jul 1984 JP
10-510471 May 1995 JP
7504120 May 1995 JP
2001-232158 Aug 2001 JP
2002-126510 May 2002 JP
2004-179014 Jun 2004 JP
2005-126966 May 2005 JP
2006-188393 Jul 2006 JP
2009-291777 Dec 2009 JP
2011-168448 Sep 2011 JP
2011-241479 Dec 2011 JP
2012-500708 Jan 2012 JP
2004-202480 Jul 2014 JP
2015-503405 Feb 2015 JP
2016-175828 Oct 2016 JP
102011008411 Jul 2011 KR
10-2012-0022164 Mar 2012 KR
1020120022164 Mar 2012 KR
1020140002570 Jan 2014 KR
WO-9333901 Mar 1993 WO
WO-9312859 Aug 1993 WO
WO-9500231 Jan 1995 WO
WO-9712664 Apr 1997 WO
WO-9830501 Jul 1998 WO
WO-0070012 Nov 2000 WO
WO-02055539 Jul 2002 WO
WO-2013115762 Aug 2003 WO
WO-2004009840 Jan 2004 WO
WO-2004082733 Sep 2004 WO
WO-2005047857 May 2005 WO
WO-2007103411 Sep 2007 WO
WO-2007140252 Dec 2007 WO
WO-2008008533 Jan 2008 WO
WO-2009129984 Oct 2009 WO
WO-2010006080 Jan 2010 WO
WO-2010115904 Oct 2010 WO
WO-2011019686 Feb 2011 WO
WO-2011046706 Apr 2011 WO
WO-2011001674 Jun 2011 WO
WO-2011063458 Jun 2011 WO
WO-2011075158 Jun 2011 WO
WO-2011094204 Aug 2011 WO
WO-2011100458 Aug 2011 WO
WO-2011138689 Nov 2011 WO
WO-2012006657 Jan 2012 WO
WO-2012021801 Feb 2012 WO
WO-2012027148 Mar 2012 WO
WO-2012028695 Mar 2012 WO
WO-2012030368 Mar 2012 WO
WO-2012125770 Sep 2012 WO
WO-2012138671 Oct 2012 WO
WO-2012142852 Oct 2012 WO
WO-2013016445 Jan 2013 WO
WO-2013048063 Apr 2013 WO
WO-2013138137 Sep 2013 WO
WO-2013138698 Sep 2013 WO
WO-2013151799 Oct 2013 WO
WO-2013152179 Oct 2013 WO
WO-2014084861 Jun 2014 WO
WO-2014168629 Oct 2014 WO
PCTUS2015018114 Feb 2015 WO
WO-2015030698 Mar 2015 WO
PCTUS2015028948 May 2015 WO
WO-2015110277 Jul 2015 WO
WO-2015138736 Sep 2015 WO
WO-2015138752 Sep 2015 WO
WO-20151138771 Sep 2015 WO
WO-2015197217 Dec 2015 WO
WO-2016102003 Jun 2016 WO
Non-Patent Literature Citations (448)
Entry
Allen et al., “Craters on silicon surfaces created by gas cluster ion impacts,” Journal of Applied Physics, 92(7): 3671-3678 (Oct. 2002).
Atmeh et al., “Albumin Aggregates: Hydrodynamic Shape and Physico-Chemical Properties,” Jordan Journal of Chemistry, 2(2): 169-182 (2007).
Chen et al., “Mechanically Strong, Electrically Conductive, and Biocompatible Graphene Paper,” Adv. Mater., 20(18): 3557-3561 (Sep. 2008) (available online Jul. 2008).
CN Office Action in Chinese Application No. 201380013988.9 dated Aug. 18, 2016 (English translation not readily available).
Fuertes, “Carbon composite membranes from Matrimid® and Kapton® polyimides for gas separation,” Microporous and Mesoporous Materials, 33: 115-125 (1991).
Galashev, “Computer study of the removal of Cu from the graphene surface using Ar clusters,” Computational Materials Science, 98: 123-128 (Feb. 2015) (available online Nov. 2014).
International Search Report and Written Opinion in PCT/US2015/013599 dated Jul. 20, 2015.
International Search Report and Written Opinion in PCT/US2015/013805 dated Apr. 30, 2015.
International Search Report and Written Opinion in PCT/US2015/018114 dated Jun. 3, 2015.
International Search Report and Written Opinion in PCT/US2015/020246 dated Jun. 10, 2015.
International Search Report and Written Opinion in PCT/US2015/020296 dated Jun. 17, 2015.
International Search Report and Written Opinion in PCT/US2015/028948 dated Jul. 16, 2015.
International Search Report and Written Opinion in PCT/US2015/029932 dated Oct. 6, 2015.
Inui et al., “Molecular dynamics simulations of nanopore processing in a graphene sheet by using gas cluster ion beam,” Appl. Phys. A, 98: 787-794 (Mar. 2010) (available online Dec. 2009).
Koh et al., “Sensitive NMR Sensors Detect Antibodies to Influenza,” NIH PA Author Manuscript PMC (Apr. 2009), also published in Angew. Chem. Int'l Engl, 47(22): 4119-4121 (May 2008) (available online Apr. 2008).
Lehtinen et al., “Cutting and controlled modification of graphene with ion beams,” Nanotechnology, 22: 175306 (8 pages) (Mar. 2011).
Matteucci et al., “Transport of gases and Vapors in Glass and Rubbery Polymers,” in Materials Science of Membranes for Gas and Vapor Separation. (Yampolskii et al., eds. 2006) (available online Jun. 2006).
O'Hern et al., “Development of process to transfer large areas of LPCVD graphene from copper foil to a porous support substrate,” 1-62 (M.S. Thesis, Massachusetts Institute of Technology, Thesis) (Sep. 2011).
Plant et al. “Size-dependent propagation of Au nanoclusters through few-layer graphene,” Nanoscale, 6: 1258-1263 (2014) (available online Oct. 2013).
Popok. “Cluster Ion Implantation in Graphite and Diamond: Radiation Damage and Stopping of Cluster Constituents,” Reviews on Advanced Materials Science, 38(1): 7-16 (2014).
Russo et al., “Atom-by-atom nucleation and growth of graphene nanopores,” PNAS 109(16): 5953-5957 (Apr. 2012).
U.S. Notice of Allowance in U.S. Appl. No. 14/610,770 dated Aug. 12, 2016.
U.S. Office Action in U.S. Appl. No. 14/656,190 dated Aug. 29, 2016.
U.S. Office Action for U.S. Appl. No. 14/656,580 dated Jun. 2, 2016.
U.S. Office Action in U.S. Appl. No. 14/819,273 dated Jul. 6, 2016.
U.S. Office Action for U.S. Appl. No. 14/856,198 dated Jun. 3, 2016.
Yoon, “Simulations show how to turn graphene's defects into assets,” ScienceDaily (Oct. 4, 2016), www.sciencedaily.com/releases/2016/10/161004120428.htm.
Zabihi et al., “Formation of nanopore in a suspended graphene sheet with argon cluster bombardment: A molecular dynamics simulation study,” Nuclear Instruments and Methods in Physics Research B, 343: 48-51: Jan. 2015 (available online Nov. 2014).
Zhang et al. Modern Thin-Film Technology 284-285 (Metallurgical Industry Press, 1st ed. 2009) (English translation not readily available).
Zhao et al. (2012), “Effect of SiO2 substrate on the irradiation-assisted manipulation of supported graphene: a molecular dynamics study,” Nanotechnology 23(28): 285703 Jul. 2012 (available online Jun. 2012).
Zhao et al. May 2012, “Drilling Nanopores in Graphene with Clusters: A Molecular Dynamics Study,” J. Phys. Chem. C, 116(21): 11776-11178 (2012) (available online May 2012).
Dong et al., “Growth of large-sized graphene thin-films by liquid precursor-based chemical vapor deposition under atmospheric pressure,” Carbon 49(11): 3672-3678 May 2011.
Hong et al., “Graphene multilayers as gates for multi-week sequential release of proteins from surfaces,” NIH-PA Author Manuscript PMC (Jun. 1, 2014), also published in ACS Nano, Jan. 24, 2012; 6(1): 81-88 (first published online Dec. 29, 2011).
Hu et al., “Enabling graphene oxide nanosheets as water separation membranes,” Environmental Science & Technology, 47(8): 3715-3723 Mar. 14, 2013.
International Search Report and Written Opinion of the International Searching Authority dated Jul. 22, 2016, from related international patent application PCT/US2016/027607.
International Search Report and Written Opinion of the International Searching Authority dated Jul. 22, 2016, from related international patent application PCT/US2016/027616.
International Search Report and Written Opinion of the International Searching Authority dated Jul. 22, 2016, from related PCT application PCT/US2016/027596.
International Search Report and Written Opinion of the International Searching Authority dated Jul. 22, 2016, from related PCT application PCT/US2016/027603.
International Search Report and Written Opinion of the International Searching Authority dated Jul. 22, 2016, from related PCT application PCT/US2016/027610.
International Search Report and Written Opinion of the International Searching Authority dated Jul. 22, 2016, from related PCT application PCT/US2016/027612.
International Search Report and Written Opinion of the International Searching Authority dated Jun. 22, 2016, from related PCT application PCT/US2016/027637.
Kurapati et al., “Graphene oxide based multilayer capsules with unique permeability properties: facile encapsulation of multiple drugs,” Chemical Communication 48: 6013-6015 (Apr. 25, 2012).
Li et al., “3D graphene oxide-polymer hydrogel: near-infrared light-triggered active scaffold for reversible cell capture and on-demand release,” Advanced Materials 25: 6737-6743 Oct. 7, 2013.
Marquardt et al., “Hybrid materials of platinum nanoparticles and thiol-functionalized graphene derivatives,” Carbon 66: 285-294 (Jan. 2014; first published online Sep. 12, 2013).
Nam et al., “Monodispersed PtCo nanoparticles on hexadecyltrimethylammonium bromide treated graphene as an effective oxygen reduction reaction catalyst for proton exchange membrane fuel cells,” Carbon 50: 3739-3747 (Aug. 2012; first published online Apr. 5, 2012).
Nandamuri et al., “Chemical vapor deposition of graphene films,” Nanotechnology 21(14): 1-4 Mar. 10, 2010.
Nayini et al., “Synthesis and characterization of functionalized carbon nanotubes with different wetting behaviors and their influence on the wetting properties of carbon nanotubes/polymethylmethacrylate coatings,” Progress in Organic Coatings 77(6): 1007-1014 Mar. 2014.
Sun et al., “Growth of graphene from solid carbon sources,” Nature 468(7323): 549-552 (Nov. 25, 2010; including corrigendum in Nature 471(7336): 124 Mar. 2011.
Tang et al., “Highly wrinkled cross-linked graphene oxide membranes for biological and charge-storage applications,” Small 8(3): 423-431 (Feb. 6, 2012; first published online Dec. 13, 2011).
Adiga et al., “Nanoporous Materials for Biomedical Devices,” JOM 60: 26-32 (Mar. 25, 2008).
AMI Applied Membranes Inc. (undated). FilmTec Nanofiltration Membrane Elements. Retrieved Jun. 1, 2016, from http://www.appliedmembranes.com/filmtec-nanofiltration-membrane-elements.html.
APEL, “Track etching technique in membrane technology,” Radiation Measurements 34(1-6): 559-566 (Jun. 2001).
Bae et al., “Roll-to-roll production of 30-inch graphene films for transparent electrodes,” Nature Nanotechnology 5: 574-578 (Jun. 20, 2010).
Bai et al., “Graphene nanomesh,” Nature Nanotechnology 5: 190-194 (Feb. 14, 2010).
Baker. (2004). “Track-etch Membranes.” In Membrane Technology and Applications (2nd ed., pp. 92-94). West Sussex, England: John Wiley & Sons.
Butler et al. “Progress, Challenges, and Opportunities in Two-Dimensional Materials Beyond Graphene”, Materials Review 7(4): 2898-2926 (Mar. 6, 2013).
Chhowalla et al., “The chemistry of two-dimensional layered transition metal dichalcogenide nanosheets,” Nature Chemistry 5: 263-275 (Mar. 20, 2013).
Childres et al., “Effect of oxygen plasma etching on graphene studied using Raman spectroscopy and electronic transport measurements,” New Journal of Physics 13 (Feb. 10, 2011).
Clochard. (undated). Radiografted track-etched polymer membranes for research and application [Scholarly project]. In Laboratoire Des Solides Irradiés. Retrieved Jun. 2, 2016, from http://iramis.cea.fr/radiolyse/5juin2015/Clochard.pdf.
Cohen-Tanugi et al, “Water Desalination across Nanoporous Graphene,” ACS Nano Letters 12(7): 3602-3608 (Jun. 5, 2012).
Cohen-Tanugi, “Nanoporous graphene as a water desalination membrane,” Thesis: Ph.D., Massachusetts Institute of Technology, Department of Materials Science and Engineering (Jun. 2015).
Colton, “Implantable biohybrid artificial organs,” Cell Transplantation 4(4): 415-436 (Jul.-Aug. 1995).
Desai et al., “Nanoporous microsystems for islet cell replacement,” Advanced Drug Delivery Reviews 56: 1661-1673 (Jul. 23, 2004).
Fischbein et al., “Electron beam nanosculpting of suspended graphene sheets,” Applied Physics Letters 93(113107): 1-3, (Sep. 16, 2008).
Fissell et al., “High-Performance Silicon Nanopore Hemofiltration Membranes,” NIH-PA Author Manuscript, PMC, (Jan. 5, 2010), also published in J. Memb. Sci. 326(1): 58-63 (Jan. 5, 2009).
Gimi et al., “A Nanoporous, Transparent Microcontainer for Encapsulated Islet Therapy,” J. Diabetes Sci. Tech. 3(2): 1-7 (Mar. 2009).
International Search Report dated Dec. 4, 2015, in related international application PCT/US2015/048205.
International Search Report dated Jun. 10, 2015, from related international application PCT/US15/20201.
Jiang et al., “Porous Graphene as the Ultimate Membrane for Gas Separation,” Nano Letters 9(12): 4019-4024 (Sep. 23, 2009).
Joshi et al., “Precise and ultrafast molecular sieving through graphene oxide membranes”, Science 343(6172): 752-754 (Feb. 14, 2014).
Kanani et al., “Permeability—Selectivity Analysis for Ultrafiltration: Effect of Pore Geometry,” NIH—PA Author Manuscript, PMC, (Mar. 1, 2011), also published in J. Memb. Sci. 349(1-2): 405 (Mar. 1, 2010).
Karan et al., “Ultrafast Viscous Permeation of Organic Solvents Through Diamond-Like Carbon Nanosheets,” Science 335: 444-447 (Jan. 27, 2012).
Kim et al., “Fabrication and Characterization of Large Area, Semiconducting Nanoperforated Graphene Materials,” Nano Letters 10(4): 1125-1131 (Mar. 1, 2010).
Kim et al., “The structural and electrical evolution of graphene by oxygen plasma-induced disorder,” Nanotechnology IOP 20(375703): 1-8 (Aug. 26, 2009).
Koski and Cui, “The New Skinny in Two-Dimensional Nanomaterials”, ACS Nano 7(5): 3739-3743 (May 16, 2013).
Liu et al., “Atomically Thin Molybdenum Disulfide Nanopores with High Sensitivity for DNA Translocation,” ACS Nano 8(3): 2504-2511 (Feb. 18, 2014).
Liu et al., “Graphene Oxidation: Thickness-Dependent Etching and Strong Chemical Doping,” Nano Letters 8(7): 1965-1970 (Jun. 19, 2008).
Mishra et al., “Functionalized Graphene Sheets for Arsenic Removal and Desalination of Sea Water,” Desalination 282: 39-45 (Nov. 1, 2011).
Morse, “Scalable Synthesis of Semiconducting Nanopatterned Graphene Materials,” InterNano Resources for Nanomanufacturing (undated). Retrieved Jun. 2, 2016 from: http://www.internano.org/node/345.
Nair et al., “Unimpeded Permeation of Water Through Helium-Leak-tight Graphene-Based Membranes,” Science 335: 442-444 (Jan. 27, 2012).
O'Hern et al. “Selective Molecular Transport through Intrinsic Defects in a Single Layer of CVD Graphene,” ACS Nano, 6(11): 10130-10138 (Oct. 2, 2012).
O'Hern et al., “Selective Ionic Transport through Tunable Subnanometer Pores in Single-Layer Graphene Membranes,” Nano Letters 14(3): 1234-1241 (Feb. 3, 2014).
Paul, “Creating New Types of Carbon-Based Membranes,” Science 335: 413-414 (Jan. 27, 2012).
Schweicher et al., “Membranes to achieve immunoprotection of transplanted islets,” NIH-PA Author Manuscript, PMC, (Nov. 13, 2014), also published in Frontiers in Bioscience (Landmark Ed) 19: 49-76 (Jan. 1, 2014).
Sint et al., “Selective Ion Passage through Functionalized Graphene Nanopores,” JACS 130: 16448-16449 (Nov. 14, 2008).
Suk et al., “Water Transport Through Ultrathin Graphene,” Journal of Physical Chemistry Letters 1(10): 1590-1594 (Apr. 30, 2010).
Tan et al., “Beta-cell regeneration and differentiation: how close are we to the ‘holy grail’?” J. Mol. Encodrinol. 53(3): R119-R129 (Dec. 1, 2014).
Vlassiouk et al., “Versatile ultrathin nanoporous silicon nitride membranes,” Proc. Natl. Acad. Sci. USA 106(50): 21039-21044 (Dec. 15, 2009).
Wadvalla, “Boosting agriculture through seawater,” Nature Middle East (Jul. 2, 2012). Retrieved Jun. 1, 2016 from: natureasia.com/en/nmiddleeast/article/10.1038/nmiddleeast.2012.92?WT.mc_id=FBK NatureMEast].
Wikipedia, “Ion track.” Jun. 1, 2016. Retrieved Jun. 1, 2016 from: en.wikipedia.org/wiki/ion_track.
Xu et al., “Graphene-like Two-Dimensional Materials”, Chemical Reviews 113: 3766-3798 (Jan. 3, 2013).
Zan et al., “Graphene Reknits Its Holes,” Nano Lett. 12(8): 3936-3940 (Jul. 5, 2012).
Zhao et al. “Two-Dimensional Material Membranes: An Emerging Platform for Controllable Mass Transport Applications,” Small 10(22): 4521-4542 (Sep. 10, 2014).
Notice of Allowance for U.S. Appl. No. 14/819,273 dated Oct. 28, 2016.
U.S. Office Action for U.S. Appl. No. 14/193,007 dated Oct. 21, 2016.
U.S. Office Action for U.S. Appl. No. 14/193,007 dated Dec. 21, 2015.
U.S. Office Action for U.S. Appl. No. 14/193,007 dated Jul. 1, 2016.
U.S. Notice of Allowance in U.S. Appl. No. 14/610,770 dated Jan. 23, 2017.
U.S. Notice of Allowance in U.S. Appl. No. 14/856,198 dated Feb. 10, 2017.
U.S. Notice of Allowance in U.S. Appl. No. 14/856,198 dated Mar. 1, 2017.
U.S. Office Action in U.S. Appl. No. 14/609,325 dated Feb. 16, 2017.
U.S. Office Action in U.S. Appl. No. 14/193,007 dated Mar. 23, 2017.
U.S. Office Action in U.S. Appl. No. 14/656,580 dated Feb. 9, 2017.
U.S. Office Action in U.S. Appl. No. 15/099,464 dated Mar. 10, 2017.
Barreiro et al. “Understanding the catalyst-free transformation of amorphous carbon into graphene by current-induced annealing,” Scientific Reports, 3 (Article 1115): 1-6 (Jan. 2013).
Botari et al., “Graphene healing mechanisms: A theoretical investigation,” Carbon, 99: 302-309 (Apr. 2016) (published online Dec. 2015).
Chen et al., “Defect Scattering in Graphene,” Physical Review Letters, 102: 236805-1-236805-4 (Jun. 2009).
Chen et al., “Self-healing of defected graphene,” Applied Physics Letters, 102(10): 103107-1-103107-5 (Mar. 2013).
Cheng et al., “Ion Transport in Complex Layered Graphene-Based Membranes with Tuneable Interlayer Spacing,” Science Advances, 2(2): e1501272 (9 pages) (Feb. 2016).
Crock et al., “Polymer Nanocomposites with Graphene-Based Hierarchical Fillers as Materials for Multifunctional Water Treatment Membranes,” Water Research, 47(12): 3984-3996 (Aug. 2013) (published online Mar. 2013).
Han et al., “Ultrathin Graphene Nanofiltration Membrane for Water Purification,” Advanced Functional Materials, 23(29): 3693-3700 (Aug. 2013).
International Search Report and Written Opinion in PCT/US2016/027583 dated Jan. 13, 2017.
Written Opinion in PCT/US2016/027590 dated Jan. 6, 2017.
International Search Report and Written Opinion in PCT/US2016/027594 dated Jan. 13, 2017.
International Search Report and Written Opinion in PCT/US2016/027628 dated Jan. 9, 2017.
International Search Report and Written Opinion in PCT/US2016/027631 dated Jan. 13, 2017.
International Search Report and Written Opinion in PCT/US2016/027632 dated Jan. 9, 2017.
Written Opinion in PCT/US2016/052010 dated Dec. 20, 2016.
International Search Report in PCT/US2016/027629 dated Dec. 8, 2016.
International Search Report in PCT/US2016/052007 dated Dec. 27, 2016.
Kjeldsen, T., “Yeast secretory expression of insulin precursors,” Appl Microbiol Biotechnol, 54: 277-286 (May 2000).
Lin et al., “A Direct and Polymer-Free Method for Transferring Graphene Grown by Chemical Vapor Deposition to Any Substrate,” ACSNANO, 8(2): 1784-1791 (Jan. 2014).
Liu et al. “Synthesis of high-quality monolayer and bilayer graphene on copper using chemical vapor deposition,” Carbon, 49(13): 4122-4130 (Nov. 2011) (published online May 2011).
O'Hern et al., “Nanofiltration across defect-sealed nanoporous monolayer graphene,” Nano Letters, 15(5): 3254-3260 (Apr. 2015).
U.S. Corrected Notice of Allowance in U.S. Appl. No. 13/480,569 dated May 26, 2015.
U.S. Notice of Allowance for U.S. Appl. No. 14/610,770 dated Apr. 25, 2016.
U.S. Notice of Allowance in U.S. Appl. No. 14/819,273 dated Dec. 14, 2016.
U.S. Notice of Allowance in U.S. Appl. No. 13/480,569 dated Feb. 27, 2015.
U.S. Office Action in U.S. Appl. No. 13/480,569 dated Jul. 30, 2014.
U.S. Office Action in U.S. Appl. No. 14/856,471 dated Dec. 1, 2016.
U.S. Restriction Requirement in U.S. Appl. No. 14/193,007 dated Jul. 17, 2015.
Wang et al., “Graphene Oxide Membranes with Tunable Permeability due to Embedded Carbon Dots,” Chemical Communications, 50(86): 13089-13092 (Nov. 2014) (published online Sep. 2014).
Xu et al., “Graphene Oxide-TiO2 Composite Filtration Membranes and their Potential Application for Water Purification,” Carbon, 62: 465-471 (Oct. 2013) (published online Jun. 2013).
Zhao et al., “A glucose-responsive controlled release of insulin system based on enzyme multilayers-coated mesoporous silica particles,” Chem. Commun., 47: 9459-9461 (Jun. 2011).
U.S. Appl. No. 14/858,741, filed Sep. 18, 2015.
U.S. Appl. No. 14/193,007, filed Feb. 28, 2014.
U.S. Appl. No. 14/856,471, filed Sep. 16, 2015.
U.S. Appl. No. 15/099,295, filed Apr. 14, 2016.
U.S. Appl. No. 15/099,410, filed Apr. 14, 2016.
U.S. Appl. No. 15/099,420, filed Apr. 14, 2016.
U.S. Appl. No. 15/099,289, filed Apr. 14, 2016.
U.S. Appl. No. 15/099,447, filed Apr. 14, 2016.
U.S. Appl. No. 15/099,269, filed Apr. 14, 2016.
U.S. Appl. No. 15/099,239, filed Apr. 14, 2016.
U.S. Appl. No. 15/099,464, filed Apr. 14, 2016.
U.S. Appl. No. 15/099,276, filed Apr. 14, 2016.
U.S. Appl. No. 15/099,482, filed Apr. 14, 2016.
U.S. Appl. No. 15/099,056, filed Apr. 14, 2016.
U.S. Appl. No. 15/099,099, filed Apr. 14, 2016.
U.S. Appl. No. 15/308,351, filed Nov. 1, 2016.
U.S. Appl. No. 14/656,190, filed Mar. 12, 2015.
U.S. Appl. No. 15/099,304, filed Apr. 14, 2016.
U.S. Appl. No. 15/099,588, filed Apr. 14, 2016.
U.S. Appl. No. 14/843,944, filed Sep. 2, 2015.
U.S. Appl. No. 15/099,193, filed Apr. 14, 2016.
U.S. Appl. No. 15/336,545, filed Oct. 27, 2016.
U.S. Appl. No. 15/289,944, filed Oct. 10, 2016.
U.S. Appl. No. 13/422,753, filed Mar. 16, 2012.
U.S. Appl. No. 13/719,579, filed Dec. 19, 2012.
U.S. Appl. No. 14/686,452, filed Apr. 14, 2015.
U.S. Appl. No. 14/200,195, filed Mar. 7, 2014.
U.S. Appl. No. 14/031,300, filed Sep. 19, 2013.
U.S. Appl. No. 13/779,963, filed Feb. 28, 2013.
U.S. Appl. No. 14/656,580, filed Mar. 12, 2015.
U.S. Appl. No. 14/656,335, filed Mar. 12, 2015.
U.S. Appl. No. 14/656,657, filed Mar. 12, 2015.
U.S. Appl. No. 14/656,617, filed Mar. 12, 2015.
U.S. Appl. No. 13/480,569, filed May 25, 2012.
U.S. Appl. No. 14/754,531, filed Jun. 29, 2015.
U.S. Appl. No. 14/610,770, filed Jan. 30, 2015.
U.S. Appl. No. 14/609,325, filed Jan. 29, 2015.
U.S. Appl. No. 14/819,273, filed Aug. 5, 2015.
U.S. Appl. No. 14/192,796, filed Feb. 27, 2014.
U.S. Appl. No. 14/707,808, filed May 8, 2015.
U.S. Appl. No. 15/589,135, filed May 8, 2017.
U.S. Appl. No. 15/332,982, filed Oct. 24, 2016.
U.S. Appl. No. 15/410,457, filed Jan. 19, 2017.
U.S. Appl. No. 15/453,441, filed Mar. 8, 2017.
U.S. Appl. No. 14/971,922, filed Dec. 16, 2015.
U.S. Appl. No. 14/195,802, filed Mar. 3, 2014.
Search and Examination Report for United Arab Emirates Application No. P186/13 dated Oct. 4, 2016. (10 pages).
Agenor et al., “Renal tubular dysfunction in human visceral leishmaniasis (Kala-azar),” Clinical Nephrology 71(5): 492-500 (May 2009) (available online Mar. 21, 2011).
Albert et al., “Ringer's lactate is compatible with the rapid infusion of AS-3 preserved packed red blood cells,” Can. J. Anaesth. 56(5): 352-356 (May 2009) (available online Apr. 2, 2009).
Aluru et al. “Modeling electronics on the nanoscale.” Handbook of nanoscience, engineering and technology Goddard W, Brenner D, Lyshevski S, Iafrate GJ (2002): 11-1.
Alvarenga, “Carbon nanotube materials for aerospace wiring” Rochester Institute of Technology, 2010.
AMI Applied Membranes Inc., “Filmtec Nanofiltration Membrane Elements”, Retrieved from appliedmembranes.com/nanofiltration_elements.htm, accessed Apr. 28, 2015 (2 Pages).
Aso et al., “Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin,” Diabetes 55(7): 1954-1960 (Jul. 2006).
AU Examination Report for Australian Patent Application No. 2013235234, dated Jan. 13, 2017, 4 pages.
AU Examination Report for Australian Patent Application No. 2013363283, dated Jun. 20, 2017, 4 pages.
AU Notice of Acceptance for Australian Application No. 2011293742 dated Jan. 13, 2016.
Australian Office Action in Application No. 2013235234 dated Dec. 19, 2017 (5 pages).
Axelsson et al., “Acute hyperglycemia induces rapid, reversible increases in glomerular permeability in nondiabetic rats,” AM. J. Physiol. Renal Physiol. 298(6): F1306-F1312 (Jun. 2010) (available online Mar. 17, 2010).
Bains et al., “Novel lectins from rhizomes of two Acorus species with mitogenic activity and inhibitory potential towards murine cancer cell lines,” Int'l Immunopharmacol. 5(9): 1470-1478 (Aug. 2005) (available online May 12, 2005).
Baker, “Membrane Technology and Applications”, Membrane Technology and Applications; Apr. 14, 2004; pp. 92-94.
Barreiro et al. “Transport properties of graphene in the high-current limit.” Physical review letters 103.7 (2009): 076601.
Bazargani et al. “Low molecular weight heparin improves peritoneal ultrafiltration and blocks complement and coagulation,” Peritoneal Dialysis Int'l 25(4): 394-404 (Jul. 2005-Aug. 2005).
Bazargani, “Acute inflammation in peritoneal dialysis: experimental studies in rats. Characterization of regulatory mechanisms,” Swedish Dental J. Supp. 171: 1-57, i (2005).
Beppu et al., “Antidiabetic effects of dietary administration of Aloe arborescens Miller components on multiple low-dose streptozotocin-induced diabetes in mice: investigation on hypoglycemic action and systemic absorption dynamics of aloe components,” J. Ethnopharmacol. 103(3): 468-77 (Feb. 20, 2006) (available online Jan. 6, 2006).
Bieri et al. “Two-dimensional Polymer Formation on Surfaces: Insight into the Roles of Precursor Mobility and Reactivity” JACS, 2010, vol. 132, pp. 16669-16676.
Bruin et al., “Maturation and function of human embryonic stem cell-derived pancreatic progenitors in macroencapsulation devices following transplant into mice”, Diabetologia (2013), vol. 56: 1987-1998 (Jun. 16, 2013).
Chu Ju, et al. “Modern Biotechnology” East China University of Technology Press, (Sep. 2007), vol. 1; pp. 306-307, ISBN 978-7-5628-2116-8.
Chu, L., et al., “Porous graphene sandwich/poly(vinylidene fluoride) composites with high dielectric properties,” Composites Science and Technology, 86, (2013), pp. 70-75.
Clochard, “Track-Etched Polymer Membranes,” Laboratory of Irradiated Solids, Ecole Polytechnique, retrieved from http://www.lsi.polytechnique.fr/home/research/physics-and-chemistry-of-nano-objects/trac . . . , Accessed Jul. 30, 2015 (2 pages).
CN Notification of Grant for Chinese Application No. 201180049184.5 dated Jun. 6, 2016.
CN Office Action for Chinese Application No. 201380014845.X dated Jul. 8, 2016.
CN Office Action for Chinese Application No. 201380014845.X dated Sep. 2, 2015.
CN Office Action for Chinese Application No. 201380019165.5 dated Aug. 25, 2015.
CN Office Action for Chinese Application No. 201380073141.X dated Jun. 8, 2016.
CN Office Action for Chinese Application No. 201380073141.X dated Mar. 21, 2017.
CN Office Action for Chinese Application No. 201480015372.X dated Aug. 2, 2016.
CN Office Action for Chinese Application No. 20118004918.5 dated Jun. 15, 2015.
CN Office Action for Chinese Application No. 201180049184.5 dated Jul. 30, 2014.
CN Office Action for Chinese Application No. 201180049184.5 dated Mar. 4, 2016. (3 pages).
CN Office Action for Chinese Application No. 201380014845.X dated Dec. 23, 2016.
CN Office Action for Chinese Application No. 201380017644.5 dated Feb. 7, 2017.
CN Office Action for Chinese Application No. 201380017644.5 dated May 26, 2016.
CN Office Action for Chinese Application No. 201380017644.5 dated Sep. 29, 2015.
CN Office Action in Chinese Application No. 201380013988.9 dated Oct. 27, 2015.
CN Office Action in Chinese Application No. 201580006829.5 dated Aug. 1, 2017. (English translation) (8 pages).
Daniel et al. “Implantable Diagnostic Device for Cancer Monitoring.” Biosens Bioelectricon. 24(11): 3252-3257 (Jul. 15, 2009).
Database WPI, Week 201238, Thomson Scientific, London, GB; AN 2012-D49442.
De Lannoy et al., “Aquatic Biofouling Prevention by Electrically Charged Nanocomposite Polymer Thin Film Membranes”, 2013 American Water Work Association membrane Technology Conference; Environmental science & technology 47.6 (2013): 2760-2768.
Deng et al., “Renal protection in chronic kidney disease: hypoxia-inducible factor activation vs. angiotensin II blockade,” Am. J. Physiol. Renal Physiol. 299(6): F1365-F1373 (Dec. 2010) (available online Sep. 29, 2010).
Edwards, “Large Sheets of Graphene Film Produced for Transparent Electrodes (w/ Video)”; (Jun. 21, 2010), PhysOrg.com, retrieved on May 15, 2017 from https://phys.org/news/2010-06-large-sheets-graphene-transparentelectrodes.html (2 pages).
EP Office Action for European Application No. 13715529.7 dated Jun. 24, 2016.
EPO Extended Search Report for European Application No. 171684883.5 dated Jul. 25, 2017 (8 pages).
EPO Supplementary Search Report for European Application No. 15743307.9 dated Aug. 9, 2017 (17 pages).
EPO Supplementary Search Report for European Application No. 15762019.6 dated Aug. 9, 2017 (16 pages).
European Extended Search Report in Application No. 15755350.4 dated Oct. 30, 2017 (9 pages).
European Extended Search Report in Application No. 15762019.6 dated Nov. 20, 2017 (12 pages).
European Extended Search Report in Application No. 15762213.5 dated Oct. 10, 2017 (8 pages).
European Search Report dated Aug. 28, 2017 from related EP application 15743750.0. (7 pages).
Fayerman, “Canadian scientists use stem cells to reverse diabetes in mice”, The Telegraph-Journal (New Brunswick), 1-2 (Jun. 29, 2012).
Fayerman, “Diabetes reversed in mice; University of B.C. scientists use embryonic stem cells to deal with Type 1 disease”, The Vancouver Sun (British Columbia), 1-2 (Jun. 28, 2012).
Fejes et al. “A review of the properties and CVD synthesis of coiled carbon nanotubes.” Materials 3.4 (2010): 2618-2642.
Franzen, C. “MIT Setting Up Industrial-Scale Graphene Printing Press” Sep. 23, 2011, retrieved from http://talkingpointsmemo.com/idealab/mit-setting-up-industrial-scale-graphene-printing-press (2 pages).
Freedman et al., “Genetic basis of nondiabetic end-stage renal disease,” Semin. Nephrol. 30(2): 101-110 (Mar. 2010).
Garcia-Lopez et al., “Determination of high and low molecular weight molecules of icodextrin in plasma and dialysate, using gel filtration chromatography, in peritoneal dialysis patients,” Peritoneal Dialysis Int'l 25(2): 181-191 (Mar. 2005-Apr. 2005).
Georgakilas et al., “Functionalization of Graphene: Covalent and Non-Covalent Approaches, Derivatives and Applications,” Chem. Rev., (2012) 112(11), pp. 6156-6214.
Gnudi “Molecular mechanisms of proteinuria in diabetes,” Biochem. Soc. Trans. 36(5): 946-949 (Oct. 2008).
Gotloib et al., “Peritoneal dialysis in refractory end-stage congestive heart failure: a challenge facing a no-win situation,” Nephrol. Dialysis. Transplant. 20(Supp. 7): vii32-vii36 (Jul. 2005).
Gu et al., “One-step synthesis of porous graphene-based hydrogels containing oil droplets for drug delivery”, Royal Society of Chemistry (RSC), vol. 4, No. 7, Jan. 1, 2014, pp. 3211-3218.
Harvey “Carbon as conductor: a pragmatic view.” Proceedings of the 61st IWCS Conference, http://www. iwcs. org/archives/56333-iwcs-2012b-1.1584632. vol. 1. 2012.
Hashimoto et al. “Direct evidence for atomic defects in graphene layers.” Nature 430.7002 (2004): 870-873.
He, et al. “The attachment of Fe3 O4 nanoparticles to graphene oxide by covalent bonding.” Carbon 48.11 (2010): 3139-3144.
Hone et al. “Graphene has record-breaking strength” Physicsworld.com, Jul. 17, 2008.
Huang et al., “Gene expression profile in circulating mononuclear cells afterexposure to ultrafine carbon particles,” Inhalation Toxicol. 22(10): 835-846 (Aug. 2010).
Humplik, et al. “Nanostructured materials for water desalination.” Nanotechnology 22.29 (2011): 292001.
International Search Report and Written Opinion dated Aug. 14, 2017 from related PCT application PCT/US2017/031537. (12 pages).
International Search Report and Written Opinion dated Jan. 5, 2012 for related International Application No. PCT/US11/47800.
International Search Report and Written Opinion dated Jul. 5, 2017 from related PCT application PCT/US2017/024147. (16 pages).
International Search Report and Written Opinion dated Mar. 12, 2014 for International Application No. PCT/US2013/074942.
International Search Report and Written Opinion for International Application No. PCT/US2011/047800 dated Jan. 5, 2012.
International Search Report and Written Opinion for PCT Application No. PCT/US2014/023027 dated Jun. 26, 2014.
International Search Report and Written Opinion in International Application No. PCT/US2013/030344 dated Jun. 19, 2013.
International Search Report and Written Opinion in International Application No. PCT/US2013/033035 dated Jun. 28, 2013.
International Search Report and Written Opinion in International Application No. PCT/US2013/033400, dated Jun. 28, 2013.
International Search Report and Written Opinion in International Application No. PCT/US2013/033403 dated Jun. 28, 2013.
International Search Report and Written Opinion in PCT/US2014/041766, dated Sep. 30, 2014.
International Search Report and Written Opinion dated Jun. 5, 2014 in International Application No. PCT/US20l4/021677.
International Search Report and Written Opinion dated Jun. 6, 2014 in International Application No. PCT/US2014/023043.
International Search Report and Written Opinion dated Dec. 16, 2014, for International Application No. PCT/US2014/051011.
International Search Report and Written Opinion dated Jun. 19, 2015, in International Application No. PCT/US2015/020287.
Inui et al. “Molecular dynamics simulations of nanopore processing in a graphene sheet by using gas cluster ion beam.” Applied Physics A: Materials Science & Processing 98.4 (2010): 787-794.
Israelachvili, “Intermolecular and Surface Forces,” 3rd ed., Chap.7.1, Sizes of Atoms, Molecules, and Ions, 2011, 1 page.
Japanese Office Action in Application No. 2015-549508 dated Nov. 7, 2017 (with English translation) (2 pages).
Japanese Office Action in Application No. 2017-002652 dated Nov. 24, 2017 (with English translation) (7 pages).
Jiang, L. et al., “Design of advanced porous grapheme materials: from grapheme nanomesh to 3D architectures”, Nanoscale, Oct. 16, 2013, vol. 6, pp. 1922-1945.
Jiao et al., “Castration differentially alters basal and leucine-stimulated tissue protein synthesis in skeletal muscle and adipose tissue,” Am. J. Physiol. Endocrinol. Metab. 297(5): E1222-1232 (Nov. 2009) (available online Sep. 15, 2009).
JP Office Action in Japanese Application No. 2015-501729 dated Dec. 9, 2016 (English translation).
JP Office Action in Japanese Application No. 2015-501729 dated Jun. 20, 2017 (English translation).
JP Office Action in Japanese Application No. 2015-501867 dated Oct. 11, 2016 (English translation).
JP Office Action in Japanese Application No. 2015-503405 dated Jun. 28, 2017. (English translation) (6 pages).
JP Office Action in Japanese Application No. 2015-503405 dated Nov. 14, 2016 (English translation).
JP Office Action in Japanese Application No. 2015-503406 dated Dec. 6, 2016 (English translation).
JP Office Action in Japanese Application No. 2015-549508 dated Jun. 27, 2017 (English translation) (7 pages).
Kang et al., “Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats,” Nephrol. Dialysis Transplant. 24(1): 73-84 (Jan. 2009).
Kang et al., “Efficient Transfer of Large-Area Graphene Films onto Rigid Substrates by Hot Pressing,” American Chemical Society Nano, 6(6): 5360-5365(May 28, 2012).
Kar et al., “Effect of glycation of hemoglobin on its interaction with trifluoperazine,” Protein J. 25(3): 202-211 (Apr. 2006) (available online Jun. 6, 2006).
Kawamoto et al., “Serum high molecular weight adiponectin is associated with mild renal dysfunction in Japanese adults,” J. Atherosclerosis Thrombosis 17(11): 1141-1148 (Nov. 27, 2011).
Khun et al. “From Microporous Regular Frameworks to Mesoporous Materials with Ultrahigh Surface Area: Dynamic reorganization of Porous Polvmer Networks” JACS, 2008; vol. 130; pp. 13333-13337.
Kim et al., “Selective Gas Transport Through Few-Layered Graphene and Graphene Oxide Membranes”, Science, vol. 342, Oct. 4, 2013, pp. 91-95 (6 total pages).
Krupka et al., “Measurements of the Sheet Resistance and Conductivity of Thin Epitaxial Graphene and SiC Films” Applied Physics Letters 96, 082101-I; Feb. 23, 2010.
Kumar et al., “Modulation of alpha-crystallin chaperone activity in diabetic rat lens by curcumin,” Molecular Vision 11: 561-568 (Jul. 26, 2005).
Lathuiliere et al., “Encapsulated Cellular Implants for Recombinant Protein Delivery and Therapeutic Modulation of the Immune System,” Journal of Applied Physics, Int. J. Mol. Sci., 16: 10578-10600 (May 8, 2015).
Lee, et al. “Measurement of the elastic properties and intrinsic strength of monolayer graphene.” science 321.5887 (2008): 385-388.
Li, R.H. “Materials for immunoisolated cell transplantation”. Adv. Drug Deliv. Rev. 33, 87-109 (1998).
Liu et al., “Graphene Oxidation: Thickness-Dependent Etching and Strong Chemical Doping,” Nano Letters 8(7): 1965-1970 (published online Jun. 19, 2008).
Lucchese et al. “Quantifying ion-induced defects and Raman relaxation length in graphene.” Carbon 48.5 (2010): 1592-1597.
Macleod et al. “Supramolecular Orderinng in Oligothiophene-Fullerene Monolayers” JACS, 2009, vol. 131, pp. 16844-16850.
Mattevi et al. “A review of chemical vapour deposition of graphene on copper.” Journal of Materials Chemistry 21.10 (2011): 3324-3334.
Miao et al. “Chemical vapor deposition of grapheme” INTECH Open Access Publisher, 2011.
MIT/MTL Center for Graphene Devices and 2D Systems, retrieved from: http://www-mtl.mit.edu/wpmu/graphene/ [retrieved from Aug. 21, 2014 archive] (3 pages).
MIT/MTL Center for Graphene Devices and 2D Systems, retrieved from: http://www-mtl.mit.edu/wpmu/graphene/ [retrieved from Mar. 4, 2015 archive] (3 pages).
Nafea, et al. “Immunoisolating semi-permeable membranes for cell encapsulation: focus on hydrogels.” J Control Release. 154(2): 110-122 (Sep. 5, 2011).
Nezlin, “Circulating non-immune IgG complexes in health and disease,” Immunol. Lett. 122(2); 141-144 (Feb. 21, 2009) (available online Feb. 2, 2009).
Norata et al., “Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status,” Nutr. Metab. Cardiovasc. Dis. 20(1): 56-63 (Jan. 2010) (available online Apr. 9, 2009).
Ogawa et al., “Exosome-like vesicles in Gloydius blomhoffii blomhoffii venom,” Toxicon 51(6): 984-993 (May 2008) (available online Feb. 19, 2008).
Ohgawara et al. “Assessment of pore size of semipermeable membrane for immunoisolation on xenoimplatntation of pancreatic B cells using a diffusion chamber.” Transplant Proc. (6): 3319-3320. 1995.
Oki et al., “Combined acromegaly and subclinical Cushing disease related to high-molecular-weight adrenocorticotropic hormone,” J. Neurosurg. 110(2): 369-73 (Feb. 2009).
Osorio et al., “Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats,” Diabetes Res. Clin. Pract. 86(3): e46-e49 (Dec. 2009) (available online Oct. 2, 2009).
Osorio et al., “Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats,” J. Nephrol. 23(5): 541-546 (Sep.-Oct. 2010).
Padidela et al., “Elevated basal and post-feed glucagon-like peptide 1 (GLP-1) concentrations in the neonatal period,” Eur. J. Endocrinol. 160(1): 53-58 (Jan. 2009) (available online Oct. 24, 2008).
Pall Corporation, “Pall Water Processing Disc-Tube Filter Technology”, Retrieved on Feb. 10, 2015, Retrieved from http://www.pall.com /pdfs/Fuels-and-Chemicals/Disc-Tube_Filter_Technology-DT100b.pdF (15 Pages).
Plant et al. “Size-dependent propagation of Au nanoclusters through few-layer grapheme,” The Royal Society of Chemistry 2013, Nanoscale.
Pollard, “Growing Graphene via Chemical Vapor” Department of Physics, Pomona College; May 2, 2011.
Rafael et al. “Cell Transplantation and Immunoisolation: Studies on a macroencapsultaion device.” From the Departments of Transplantation Pathology: Stockholm, Sweden (1999).
Rezania et al., “Enrichment of Human Embryonic Stem Cell-Derived NKX6.1-Expressing Pancreatic Progenitor Cells Accelerates the Maturation of Insulin-Secreting Cells in Vivo”, Stem Cells Regenerative Medicine, vol. 31: 2432-2442 (Jul. 29, 2013).
Rezania et al., “Maturation of Human Embryonic Stem Cell-Derived Pancreatic Progenitors Into Functional Islets Capable of Treating Pre-existing Diabetes in Mice”, Diabetes Journal, vol. 61: 2016-2029 (Aug. 1, 2012).
Ribeiro et al., “Binary Mutual Diffusion Coefficients of Aqueous Solutions of Sucrose, Lactose, Glucose, and Fructose in the Temperature Range from (298.15 to 328.15) K,” J. Chem. Eng. Data 51(5): 1836-1840 (Sep. 2006) (available online Jul. 20, 2006).
Rippe et al., “Size and charge selectivity of the glomerular filter in early experimental diabetes in rats,” Am. J. Physiol. Renal Physiol. 293(5): F1533-F1538 (Nov. 2007)(available online Aug. 15, 2007).
SA Final Rejection for Saudi Arabia Application No. 113340400 dated Jan. 28, 2016.
SA First Examination Report for Saudi Arabia Application No. 113340401 dated Apr. 28, 2015.
SA First Examination Report for Saudi Arabia Application No. 113340424 dated May 10, 2015.
SA First Examination Report for Saudi Arabia Application No. 113340426 dated May 12, 2015.
SA First Examination Report in Saudi Arabia Application No. 113340400 dated Apr. 13, 2015.
SA Second Examination Report for Saudi Arabia Application No. 113340400 dated Aug. 11, 2015.
Sanchez, et al. “Biological Interactions of Graphene-Family Nanomaterials—An Interdisciplinary Review.” Chem Res Toxicol. 25(1): 15-34 (Jan. 13, 2012).
Schweitzer, Handbook of Separation Techniques for Chemical Engineers, 1979, McGraw-Hill Book Company, pp. 2-5 to 2-8.
Search Report and Written Opinion dated Aug. 14, 2017 for Singapore Application No. 11201606287V. (10 pages).
Search Report and Written Opinion dated Aug. 22, 2017 for Singapore Application No. 11201607584P. (7 pages).
Sears et al., “Recent Developments in Carbon Nanotube Membranes for Water Purification and Gas Separation” Materials, vol. 3 (Jan. 4, 2010), pp. 127-149.
Sethna et al., “Serum adiponectin levels and ambulatory blood pressure monitoring in pediatric renal transplant recipients,” Transplantation 88(8): 1030-1037 (Oct. 27, 2009).
Singapore Search Report and Written Opinion in Application No. 11201609272T dated Oct. 5, 2017 (11 pages).
Sullivan et al., “Microarray analysis reveals novel gene expression changes associated with erectile dysfunction in diabetic rats,” Physiol. Genom. 23(2): 192-205 (Oct. 17, 2005) (available online Aug. 23, 2005).
Swett et al, “Imagining and Sculpting Graphene on the atomic scale” Oak Ridge National Laboratory's (ORNL) Center for Nanophase Materials Sciences (CNMS) Biannual Review. 1 page.
Swett et al, “Supersonic Nanoparticle Interaction with Suspended CVD Graphene”, Microsc. Microanal. 22 (Suppl 3): 1670-1671 (Jul. 25, 2016).
Takata et al., “Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes,” Hypertension 51. 2 (Feb. 2008): 534-9.
Tamborlane et al., “Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes” N Engl J Med 359;14: 1464-1476 (Oct. 2, 2008).
Tanugi et al., “Nanoporous Graphene Could Outperform Best Commercial Water Desalination Techniques,” ; ACS 2012; Jun. 25, 2012; Weftec 2012; Sep. 29-Oct. 3.
Totani et al. “Gluten binds cytotoxic compounds generated in heated frying oil.” Journal of oleo science 57.12 (2008): 683-690.
Tsukamoto et al. “Purification, characterization and biological activities of a garlic oliqosaccharide,” Journal of UOEH 30.2 (Jun. 1, 2008): 147-57.
TW Office Action in Taiwanese Application No. 102146079 dated Apr. 14, 2017. 9 Pages. (English translation).
TW Search Report in Taiwanese Application No. 102146079 dated Apr. 14, 2017. 1 page.
UMEA Universitet “Graphene nanoscrolls are formed by decoration of magnetic nanoparticles.” ScienceDaily. Aug. 15, 2013. https://www.sciencedaily.com/releases/2013/08/130815084402.htm (3 pages).
U.S. Notice of Allowance for U.S. Appl. No. 12/868,150 dated Sep. 25, 2012.
U.S. Notice of Allowance for U.S. Appl. No. 13/548,539 dated Aug. 18, 2015.
U.S. Notice of Allowance for U.S. Appl. No. 13/548,539 dated Jul. 23, 2015.
U.S. Notice of Allowance for U.S. Appl. No. 13/719,579 dated May 20 ,2016.
U.S. Notice of Allowance for U.S. Appl. No. 13/7952,76 dated Oct. 7, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 13/802,896 dated Apr. 1, 2015.
U.S. Notice of Allowance for U.S. Appl. No. 13/803,958 dated Aug. 29, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 13/803,958 dated Jun. 2, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 13/803,958 dated Sep. 12, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 13/804,085 dated Jan. 15, 2015.
U.S. Notice of Allowance for U.S. Appl. No. 13/804,085 dated Mar. 12, 2015.
U.S. Notice of Allowance for U.S. Appl. No. 13/923,503 dated Oct. 14, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 13/923,503 dated Oct. 5, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 14/200,195 dated Jul. 5, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 14/200,530 dated Aug. 1, 2016.
U.S. Notice of Allowance for U.S. Appl. No. 14/203,655 dated Dec. 9, 2016.
U.S. Notice of Allowance in U.S. Appl. No. 12/868,150 dated Sep. 25, 2012.
U.S. Notice of Allowance in U.S. Appl. No. 13/795,276 dated Jan. 19, 2017.
U.S. Notice of Allowance in U.S. Appl. No. 13/803,958 dated Aug. 29, 2016.
U.S. Notice of Allowance in U.S. Appl. No. 13/803,958 dated Sep. 12, 2016.
U.S. Notice of Allowance in U.S. Appl. No. 14/193,007 dated Sep. 6, 2017. (9 pages).
U.S. Notice of Allowance in U.S. Appl. No. 14/610,770 dated May 5, 2017.
U.S. Notice of Allowance in U.S. Appl. No. 14/610,770 dated Sep. 26, 2017. (12 pages).
U.S. Notice of Allowance in U.S. Appl. No. 14/656,580 dated May 8, 2017.
U.S. Notice of Allowance in U.S. Appl. No. 14/656,580 dated Sep. 5, 2017. (8 pages).
U.S. Notice of Allowance in U.S. Appl. No. 14/819,273 dated Jun. 9, 2017.
U.S. Notice of Allowance in U.S. Appl. No. 15/099,464 dated Nov. 16, 2017 (5 pages).
U.S. Notice of Allowance in U.S. Appl. No. 15/099,464 dated Jun. 16, 2017.
U.S. Notice of Allowance in U.S. Appl. No. 15/332,982 dated Nov. 1, 2017 (9 pages).
U.S. Notice of Allowance in U.S. Appl. No. 15/332,982 dated Sep. 21, 2017. (5 pages).
U.S. Office Action for U.S. Appl. No. 13/548,539 dated Feb. 6, 2015.
U.S. Office Action for U.S. Appl. No. 13/719,579 dated Jul. 8, 2015.
U.S. Office Action for U.S. Appl. No. 13/719,579 dated May 4, 2016.
U.S. Office Action for U.S. Appl. No. 13/795,276 dated Apr. 22, 2016.
U.S. Office Action for U.S. Appl. No. 13/795,276 dated Oct. 6, 2015.
U.S. Office Action for U.S. Appl. No. 13/802,896 dated Sep. 24, 2014.
U.S. Office Action for U.S. Appl. No. 13/803,958 dated Aug. 11, 2014.
U.S. Office Action for U.S. Appl. No. 13/803,958 dated May 28, 2015.
U.S. Office Action for U.S. Appl. No. 13/803,958 dated Nov. 18, 2015.
U.S. Office Action for U.S. Appl. No. 13/923,503 dated Mar. 22, 2016.
U.S. Office Action for U.S. Appl. No. 14/031,300 dated Jan. 20, 2016.
U.S. Office Action for U.S. Appl. No. 14/031,300 dated Jul. 7, 2015.
U.S. Office Action for U.S. Appl. No. 14/200,195 dated Mar. 21, 2016.
U.S. Office Action for U.S. Appl. No. 14/200,195 dated Nov. 4, 2015.
U.S. Office Action for U.S. Appl. No. 14/200,530 dated Feb. 29, 2016. (8 pages).
U.S. Office Action for U.S. Appl. No. 14/203,655 dated Aug. 10, 2016.
U.S. Office Action for U.S. Appl. No. 14/609,325 dated Aug. 25, 2017. (7 pages).
U.S. Office Action for U.S. Appl. No. 14/656,190 dated May 18, 2017.
U.S. Office Action for U.S. Appl. No. 14/656,657 dated Jul. 7, 2017. (7 pages).
U.S. Office Action for U.S. Appl. No. 14/686,452 dated Jun. 9, 2017.
U.S. Office Action for U.S. Appl. No. 14/856,471 dated May 31, 2017.
U.S. Office Action for U.S. Appl. No. 14/858,741 dated Dec. 1, 2016.
U.S. Office Action for U.S. Appl. No. 15/099,193 dated Jul. 19, 2017. (13 pages).
U.S. Office Action for U.S. Appl. No. 15/289,944 dated Feb. 9, 2017.
U.S. Office Action for U.S. Appl. No. 15/289,944 dated Jul. 13, 2017. (18 pages).
U.S. Office Action for U.S. Appl. No. 15/332,982 dated Aug. 18, 2017. (9 pages).
U.S. Office Action for U.S. Appl. No. 15/336,545 dated Dec. 19, 2016.
U.S. Office Action for U.S. Appl. No. 15/453,441 dated Jun. 5, 2017.
U.S. Office Action in U.S. Appl. No. 14/193,007 dated Apr. 24, 2017.
U.S. Office Action in U.S. Appl. No. 14/656,617 dated Apr. 4, 2017.
U.S. Office Action in U.S. Appl. No. 14/707,808 dated Nov. 6, 2017 (27 pages).
U.S. Office Action in U.S. Appl. No. 15/099,099 dated Oct. 5, 2017 (11 pages).
U.S. Office Action in U.S. Appl. No. 15/099,193 dated Dec. 28, 2017 (25 pages).
U.S. Office Action in U.S. Appl. No. 15/099,304 dated Nov. 24, 2017 (23 pages).
U.S. Office Action in U.S. Appl. No. 15/099,447 dated Oct. 3, 2017 (21 pages).
U.S. Office Action on U.S. Appl. No. 14/656,335 dated Apr. 25, 2017.
U.S. Office Action on U.S. Appl. No. 15/332,982 dated Jan. 30, 2017.
Vallon,“Micropuncturing the nephron,” Pflugers Archiv : European journal of physiology 458. 1 (May 2009): 189-201.
Van Der Zande et al. “Large-scale arrays of single-layer graphene resonators.” Nano letters 10.12 (2010): 4869-4873.
Verdonck, P., “Plasma Etching”, in Oficina de Microfabricao: Projeto e Construcao de CI's MOS, Swart, J.W., Ed., Campinas (Sao Paulo, Brazil): UNICAMP, 2006, ch. 10, p. 9.
Vlassiouk et al. “Large scale atmospheric pressure chemical vapor deposition of graphene.” Carbon 54 (2013): 58-67.
Vriens et al. “Methodological considerations in quantification of oncological FDG PET studies.” European journal of nuclear medicine and molecular imaging 37.7 (2010): 1408-1425.
Wang et al., “Direct Observation of a Long-Lived Single-Atom Catalyst Chiseling Atomic Structures in Graphene,” Nano Lett., 2014, pp. A-F.
Wang et al., “Porous Nanocarbons: Molecular Filtration and Electronics,” Advances in Graphene Science, Edited by Mahmood Aliofkhazraei, (2013) ISBN 978-953-51-1182-5, Publisher: InTech; Chapter 6, pp. 119-160.
Wang et al., “What is the role of the second “structural” NADP+-binding site in human glucose 6-phosphate dehydrogenase?,”Protein science a publication of the Protein Society 17. 8 (Aug. 2008): 1403-11.
Wang, M., et al., “Interleaved Porous Laminate Composed of Reduced Graphene Oxide Sheets and Carbon Black Spacers by in-Situ Electrophoretic Deposition,” The Royal Society of Chemistry (2014), pp. 1-3.
Wei et al., “Synthesis of N-doped graphene by chemical vapor deposition and its electrical properties”, Nano Lett. 2009 9 1752-58.
Weisen, et al., “Fabrication of nanopores in a graphene sheet with heavy ions: A molecular dynamics study”, Journal of Applied Physics 114, 234304 (2013), pp. 234304-1 to 234304-6.
Wimalasiri, Y., et al., “Carbon nanotube/graphene composite for enhanced capacitive deionization performance,” Carbon 59 (2013), pp. 464-471.
Xiaogan Liang et al., Formation of Bandgap and Subbands in Graphene Nanomeshes with Sub-10nm Ribbon Width Fabricated via Nanoimprint Lithography., Nano Letters, Jun. 11, 2010, pp. 2454-2460.
Xie et al., “Fractionation and characterization of biologically-active polysaccharides from Artemisia tripartite,” Phytochemistry 69. 6 (Apr. 2008): 1359-71.
Xie, et al. “Controlled fabrication of high-quality carbon nanoscrolls from monolayer graphene.” Nano letters 9.7 (2009): 2565-2570.
Yagil et al. “Nonproteinuric diabetes-associated nephropathy in the Cohen rat model of type 2 diabetes” Diabetes 54. 5 (May 2005): 1487-96.
Zan et al. “Interaction of Metals with Suspended Graphene Observed by Transmission Electron Microscopy”, J. Phys. Chem. Lett., Mar. 8, 2012, 3, 953-958.
Zhang et al. “Effect of Chemical Oxidation on the Structure of Single-Walled Carbon Nanotubes”, J. Phys. Chem., Feb. 12, 2003, B 107 3712-8.
Zhang et al. “Method for anisotropic etching of graphite or graphene” Institute of Physics, Chinese Academy of Sciences; PEOP. Rep. China; Mar. 30, 2011.
Zhang et al. “Production of Graphene Sheets by Direct Dispersion with Aromatic Healing Agents”, Small, May 6, 2010, vol. 6, No. 10, 1100-1107.
Zhang et al. “Isolation and activity of an alpha-amylase inhibitor from white kidney beans,” Yao xue xue bao=Acta pharmaceutica Sinica 42. 12 (Dec. 2007): 1282-7.
Zhao, et al. “Efficient preparation of large-area graphene oxide sheets for transparent conductive films.” ACS nano 4.9 (2010): 5245-5252.
Zhou, K., et al., “One-pot preparation of graphene/ Fe304 composites by a solvothermal reaction,” New J. Chem., 2010, 34, 2950.
Zhu et al. “Carbon Nanotubes in Biomedicine and Biosensing”, Carbon Nanotubes-Growth and Applications, InTech, (Aug. 9, 2011) Chapter 6: pp. 135-162. Available from: https://www.intechopen.com/books/carbon-nanotubes-growth-and-applications/carbon-nanotubes-in-biomedicine-and-biosensing.
Ziegelmeier et al. “Adipokines influencing metabolic and cardiovascular disease are differentially regulated in maintenance hemodialysis,” Metabolism: clinical and experimental 57. 10 (Oct. 2008): 1414-21.
Zirk et al. “A refractometry-based glucose analysis of body fluids,” Medical engineering & physics 29. 4 (May 2007): 449-58.
Zyga “Nanoporous Graphene Could Outperform Best Commercial Water Desalination Techniques,” Phys.org., Jun. 22, 2012, Retrieved from http://www.phys.org/pdf259579929.pdf [Last Accessed Dec. 3, 2014] (3 pages)
Chen et al., “Hierarchically porous graphene-based hybrid electrodes with excellent electrochemical performance”, Journal of Materials Chemistry A: Materials for Energy and Sustainability, vol. 1, No. 33, Jan. 1, 2013, pp. 9409-9413.
Chinese Office Action in Application No. 201580006829.5 dated Jan. 23, 2018 (with English translation) (13 pages).
European Extended Search Report in Application No. 15786691.4 dated Dec. 1, 2017 (10 pages).
European Extended Search Report in Application No. 15789852.9 dated Dec. 6, 2017 (8 pages).
Japanese Office Action in Application No. 2017-042023 dated Jan. 9, 2018 (with English translation) (9 pages).
Singapore Search Report and Written Opinion in Application No. 11201701654U dated Dec. 6, 2017 (6 pages).
Taiwanese Office Action in Application No. 102146079 dated Dec. 12, 2017 (with English translation) (4 pages).
U.S. Office Action for U.S. Appl. No. 15/099,482 dated Feb. 23, 2018 (9 pages).
U.S. Office Action in U.S. Appl. No. 14/609,325 dated Jan. 16, 2018 (11 pages).
U.S. Office Action in U.S. Appl. No. 14/656,190 dated Jan. 10, 2018 (14 pages).
U.S. Office Action in U.S. Appl. No. 14/856,471 dated Jan. 11, 2018 (36 pages).
U.S. Office Action in U.S. Appl. No. 15/099,099 dated Feb. 15, 2018 (13 pages).
U.S. Office Action in U.S. Appl. No. 15/099,588 dated Feb. 1, 2018 (6 pages).
Wang et al., “Preparation of high-surface-area carbon nanoparticle/graphene composites”, Carbon, Elsevier, Oxford, GB, vol. 50, No. 10, Apr. 8, 2012, pp. 3845-3853.
Office Action for Indian Appl. Ser. No. 1566/DELNP/2013 dated Feb. 2, 2018 (7 pages).
Office Action for Japanese Appl. Ser. No. 2016-521448 dated Mar. 16, 2018 (5 pages).
U.S. Notice of Allowance for U.S. Appl. No. 15/099,464 dated Feb. 28, 2018 (5 pages).
U.S. Office Action for U.S. Appl. No. 15/099,276 dated Mar. 22, 2018 (13 pages).
U.S. Office Action for U.S. Appl. No. 15/453,441 dated Mar. 22, 2018 (7 pages).
Related Publications (1)
Number Date Country
20160058932 A1 Mar 2016 US
Provisional Applications (1)
Number Date Country
62044877 Sep 2014 US